

Original Paper

# Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review

Jackson M Steinkamp<sup>1</sup>, BA; Nathaniel Goldblatt<sup>2</sup>, BS; Jacob T Borodovsky<sup>3</sup>, PhD; Amy LaVertu<sup>4</sup>, MLS; Ian M Kronish<sup>5</sup>, MD, MPH; Lisa A Marsch<sup>6</sup>, PhD; Zev Schuman-Olivier<sup>2,6,7</sup>, MD

<sup>1</sup>Boston University School of Medicine, Boston, MA, United States

<sup>2</sup>Outpatient Addiction Services, Department of Psychiatry, Cambridge Health Alliance, Somerville, MA, United States

<sup>3</sup>Washington University School of Medicine, St Louis, MO, United States

<sup>4</sup>Tufts University School of Medicine, Boston, MA, United States

<sup>5</sup>Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, New York City, NY, United States

<sup>6</sup>Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States

<sup>7</sup>Department of Psychiatry, Harvard Medical School, Boston, MA, United States

**Corresponding Author:**

Zev Schuman-Olivier, MD

Outpatient Addiction Services

Department of Psychiatry

Cambridge Health Alliance

26 Central Street

Outpatient Addiction Services

Somerville, MA, 02143

United States

Phone: 1 617 591 6056

Fax: 1 617 591 6054

Email: [zschuman@cha.harvard.edu](mailto:zschuman@cha.harvard.edu)

## Abstract

**Background:** Medication adherence is critical to the effectiveness of psychopharmacologic therapy. Psychiatric disorders present special adherence considerations, notably an altered capacity for decision making and the increased street value of controlled substances. A wide range of interventions designed to improve adherence in mental health and substance use disorders have been studied; recently, many have incorporated information technology (eg, mobile phone apps, electronic pill dispensers, and telehealth). Many intervention components have been studied across different disorders. Furthermore, many interventions incorporate multiple components, making it difficult to evaluate the effect of individual components in isolation.

**Objective:** The aim of this study was to conduct a systematic scoping review to develop a literature-driven, transdiagnostic taxonomic framework of technology-based medication adherence intervention and measurement components used in mental health and substance use disorders.

**Methods:** This review was conducted based on a published protocol (PROSPERO: CRD42018067902) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses systematic review guidelines. We searched 7 electronic databases: MEDLINE, EMBASE, PsycINFO, the Cochrane Central Register of Controlled Trials, Web of Science, Engineering Village, and ClinicalTrials.gov from January 2000 to September 2018. Overall, 2 reviewers independently conducted title and abstract screens, full-text screens, and data extraction. We included all studies that evaluate populations or individuals with a mental health or substance use disorder and contain at least 1 technology-delivered component (eg, website, mobile phone app, biosensor, or algorithm) designed to improve medication adherence or the measurement thereof. Given the wide variety of studied interventions, populations, and outcomes, we did not conduct a risk of bias assessment or quantitative meta-analysis. We developed a taxonomic framework for intervention classification and applied it to multicomponent interventions across mental health disorders.

**Results:** The initial search identified 21,749 results; after screening, 127 included studies remained (Cohen kappa: 0.8, 95% CI 0.72-0.87). Major intervention component categories include reminders, support messages, social support engagement, care team contact capabilities, data feedback, psychoeducation, adherence-based psychotherapy, remote care delivery, secure medication

storage, and contingency management. Adherence measurement components include self-reports, remote direct visualization, fully automated computer vision algorithms, biosensors, smart pill bottles, ingestible sensors, pill counts, and utilization measures. Intervention modalities include short messaging service, mobile phone apps, websites, and interactive voice response. We provide graphical representations of intervention component categories and an element-wise breakdown of multicomponent interventions.

**Conclusions:** Many technology-based medication adherence and monitoring interventions have been studied across psychiatric disease contexts. Interventions that are useful in one psychiatric disorder may be useful in other disorders, and further research is necessary to elucidate the specific effects of individual intervention components. Our framework is directly developed from the substance use disorder and mental health treatment literature and allows for transdiagnostic comparisons and an organized conceptual mapping of interventions.

(*JMIR Ment Health* 2019;6(3):e12493) doi:[10.2196/12493](https://doi.org/10.2196/12493)

## KEYWORDS

systematic review; mental health; substance-related disorders; mHealth; psychiatry; medication adherence; medication compliance

## Introduction

### Background

Medication adherence—the set of behaviors relevant to taking one’s medication as directed—is critical to the effectiveness of pharmacologic therapies and improvement of patient outcomes. Psychiatric and substance use disorders are no exception to this rule; studies have repeatedly demonstrated the association between different measures of medication adherence and a wide variety of psychiatric outcomes. Medication nonadherence among individuals with schizophrenia has been shown to be associated with violence [1], hospital admission [2], and mortality [3]. Among those with mood disorders (eg, major depressive disorder and bipolar disorder), nonadherence is associated with hospitalizations, suicide risk, and slower initial recovery [4,5]. Nonadherence can be particularly problematic when treating those with opioid use disorders, as it is associated with treatment dropout [6], which is in turn associated with continued use of illicit drugs [7] and increased mortality [8]. Such studies strongly suggest the important role played by medication adherence across psychiatric disorders. The prevalence of nonadherence in these disorders is also quite high; studies estimate that 41% to 50% of patients with schizophrenia [9], 13% to 52% of those with depression [10], 57% of those with anxiety [11], and 68% of those with opioid use disorder [12] are not fully adherent to their medication. Outside of clinical practice, nonadherence and inaccurate adherence measurement stymie research studies of new interventions; clinical trials must recruit more participants, spend more money, and may even produce erroneous results because of nonadherence [13,14].

Clinicians have been struggling to solve the medication adherence problem for decades; the body of research conducted across a wide variety of medical disorders is large and continues to grow rapidly [15]. The etiologies of nonadherence are complex and multifactorial; perhaps the most common framework includes 5 major categories—socioeconomic factors, health system-related factors, condition-related factors, treatment-related factors, and patient-related factors [16]. In psychiatry, the Perceptions and Practicalities Approach classifies modifiable risk factors of nonadherence into a “*perceptual*” category (relating to patient beliefs, eg, about the presence and severity of their disorder, medication efficacy, and side effect

profile) and a *practical* category (eg, resources necessary to acquire medication and cognitive capacity to adhere despite adequate motivation)—suggesting 2 broad targets for intervention [17]. Somewhat parallel to this is the distinction between *voluntary* nonadherence (eg, due to lack of insight or desire) and *involuntary* nonadherence (eg, due to cognitive limitations, poor understanding, or simply forgetting) [18].

Mental health and substance use disorders present unique challenges to adherence owing to the nature of the symptoms associated with these disorders. The delusional belief systems and poor insight often found in schizophrenia appear to be associated with lower levels of adherence [9,19]. The street value of opioid partial agonists (the cornerstone of modern office-based opioid treatment for opioid use disorders) raises the specter of medication diversion and provides a strong incentive for nonadherence. Patients with posttraumatic stress disorder (PTSD), in particular PTSD induced by *medical* events, are more likely to be nonadherent to medication regimens—it has been proposed that the medications may serve as aversive reminders that trigger avoidant behaviors [20]. Depressed patients are much less likely to adhere to medication regimens [21], likely mediated through a decreased motivation for self-care [22]. At least one study has linked anxiety disorders to increased medication nonadherence [23], though other studies have found mixed results [24]. Across all psychiatric disorders, the self-stigma associated with receiving treatment for mental illness has also been shown to contribute to nonadherence [25]. In particular, these challenges may motivate an increased emphasis on adherence *monitoring* in addition to adherence motivation, relative to nonpsychiatric disorders.

In the past few decades, information technology and related fields have enabled a wide variety of new approaches and modalities to improve medication adherence and adherence monitoring. The near-ubiquity of mobile phones [26], the relative ease of app development, the boom in Internet of Things devices capable of recording and transmitting real-time biological data, and the steady improvement of artificial intelligence (AI) and machine learning systems have all contributed to this increase in technology-based interventions for medication adherence.

The field of technological interventions for medication adherence in psychiatric disorders is quite young and expanding

in scope, with multiple new trials each year in each disorder context. Many intervention types have been studied only in pilot studies, or in randomized controlled trials (RCTs) with small sample sizes. Furthermore, many interventions consist of multiple components used in conjunction, which complicates the study of the efficacy of individual intervention components. Significant additional research needs to be done before we can determine which technology-based interventions are most promising.

Recent related research in summarizing the vast and diverse field of psychiatric medication adherence technologies includes systematic reviews focusing on particular disorders such as mood disorders [27], schizophrenia and other psychotic disorders [28,29], and substance use disorders [30]. Other reviews evaluate specific technologic intervention types, including automated reminders [31], adherence monitoring [32], and virtual reality technologies [33]. However, given the breadth, size, and expansion rate of this field, little research has been done to compare and contrast feasibility and effectiveness of various interventions *across* disorder contexts, or to provide a transdiagnostic framework of adherence intervention components. Although the efficacy of specific interventions may ultimately prove to differ between diagnoses, we believe that the etiologies of nonadherence and the frequently studied intervention components are similar enough to justify such a transdiagnostic approach. In this review, we also evaluate this assumption formally.

## Objective

Here, we conduct a systematic scoping review of the literature concerning technology-based solutions for medication nonadherence among those with psychiatric disorders. The review is designed to provide a broad transdiagnostic overview of research themes and intervention types, with an eye toward developing a data-driven conceptual framework of technology-based adherence interventions for mental health and substance use disorders. We believe that such a framework would aid researchers in evaluating new literature, create promising directions for future research, and provide a summary of this vast field for the busy clinician who may be overwhelmed by the panoply of available options. In the long term, new multicomponent interventions might be built quickly and effectively by sampling promising components from this framework, based on domain-specific knowledge from a researcher or clinician's area of study.

## Methods

### Overview

This is a systematic scoping review of technological interventions designed to improve medication adherence in mental health and substance use populations. We define technology broadly, including software, hardware, algorithms, and biosensors. This review was conducted based on a published protocol (PROSPERO: CRD42018067902). We conducted a qualitative synthesis of themes in the included literature, constructed graphical concept maps and graphed topic area popularity over time in different psychiatric disorder contexts. We aimed to provide a comprehensive transdiagnostic

framework with which to think about and categorize components of technological interventions for medication adherence in mental health and substance use populations.

### Search Strategy

To obtain relevant scientific literature, we searched 7 electronic bibliographic databases: MEDLINE, EMBASE, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Engineering Village, and ClinicalTrials.gov. Study records identified from ClinicalTrials.gov were used to search for related published articles and conference proceedings. Reference lists from the included studies as well as reviews on related topics were searched for additional relevant articles. Authors were contacted to answer specific questions when necessary.

Using the Population-Intervention-Comparison-Outcome (PICO) framework [34], 3 core thematic concepts were used to build the search strategy: mental health and substance use disorders (population), technology (intervention), and medication adherence or compliance (outcome); all 3 of which were necessary for article inclusion. We constructed the final search strategy through an iterative collaborative process, which included reading related review articles, building a tree of relevant MeSH terms, and testing searches against a growing corpus of "must-include" articles identified through a preliminary search. Furthermore, we consulted with multiple research librarians to ensure our strategy was comprehensive and database-specific.

We searched by title or keyword, using MeSH terms for MEDLINE and analogous terms for other databases when applicable (eg, Emtree). We initially included English language articles published between January 2000 and January 2018; articles from before 2000 were unlikely to be relevant from a technological perspective. Reviews, letters, case reports, editorials, and other forms of nonprimary research were excluded. Journal articles, conference proceedings, and abstracts were included if they represented primary research. Given the broad scope and heterogeneity of the topic, we included all study designs, ranging from RCTs to pilot feasibility studies to provide a comprehensive concept map. For completeness, a search for any updated manuscripts was rerun on MEDLINE, EMBASE, PsycINFO, CENTRAL, and Web of Science during September 2018. The full search strategies are listed in [Multimedia Appendix 1](#).

### Inclusion Criteria

#### Adherence

Much of the literature around technological adherence interventions relates to improving the accuracy of adherence *measurement* (eg, ingestible biosensors, smart pill bottles, and directly observed remote medication ingestion). Accurate adherence measurement is critical for evaluating the efficacy of interventions both in clinical practice and in research studies, it and is a critical part of many multicomponent interventions. We therefore considered a study to meet the *adherence* criteria of inclusion if the intervention was designed to improve either medication adherence or the accuracy of adherence measurement. We excluded articles which evaluated participant

adherence to the intervention as a whole, or a component of the intervention other than adherence to pharmacologic therapy (for instance, a study evaluating whether participants were adherent to a Web-based psychoeducational program). Articles that did not directly measure medication adherence or medication adherence measurement accuracy as an outcome (eg, pilot feasibility or usability studies) were included if medication adherence was a key motivating factor for development of the intervention, as assessed by the abstract, introduction, and discussion sections of the article.

### Technology

Given the aim of the scoping review, we defined technology as broadly as possible. We wanted to include all forms of modern information technology such as mobile phones, mobile apps, websites, and computer vision-based (CV) AI systems, as well as interactive voice response (IVR) technology. Furthermore, physical technology such as smart pill bottles and ingestible sensors, as well as studies of novel biomarkers or biological measurement methods, were considered to meet the *technology* criterion for inclusion. Many of the multicomponent interventions found throughout the course of the search contained some technological components while also containing other components that did not meet our definition of technology-based; we included these studies and will describe the technological components therein to provide the most comprehensive map of the space.

### Other Exclusions

We excluded articles that did not exclusively study a psychiatric or substance use population (although we did include articles in which all the participants had an additional nonpsychiatric condition—eg, patients with HIV and opioid use disorder). We excluded epidemiologic studies that only examined the prevalence of nonadherence. We excluded studies which provided only financial incentive for medication adherence with no other components. We excluded protocol-only articles if outcome articles were available for the same study. We excluded articles focusing on pediatric populations, as their caretakers are often responsible for their adherence behaviors. Similarly, we excluded studies of patients with dementia disorders, as they often have caretakers who are responsible for adherence behaviors.

### Study Selection and Extraction

We used the Cochrane Covidence tool [35] to assist in conducting most of the systematic review. To be included, an article had to be deemed relevant at 2 stages—1) title and abstract screen and 2) full-text screen. Overall, 2 reviewers (JMS and NG) independently screened each abstract and full-text article. Conflicts were resolved via discussion until consensus was reached; a third reviewer (JB) was on hand to resolve disagreements, but this was not needed for this review. Interrater reliability was calculated for both the title-abstract stage and the full-text screening stage using Cohen kappa.

Included articles were then extracted using a charting tool developed iteratively by the authors. Both reviewers (JS and

NG) performed extraction on each of the articles and compared the extracted results. Extracted data fields included the following: author's name, year of publication, study objectives (primarily targeted at improving adherence, measurement accuracy, or both), population (eg, opioid use disorder or bipolar disorder), study type (eg, RCT or pilot feasibility), study size, components of intervention delivered technologically (eg, reminders, education, support, or monitoring), and technological modality when applicable (eg, app, website, or IVR). We did not assess risk of bias or study quality given the large amount of heterogeneity in study populations, study designs, intervention types, and outcome measures as well as the goal to conduct a systematic scoping review.

Before starting the review, we chose to make a top-level distinction between *data collection components* (system components designed to collect data or improve the accuracy of adherence measurement) and *interventional components* (system components designed to directly increase medication adherence).

Results were labeled as including a data collection component if the study either (1) evaluated the accuracy of a measurement method (for instance, a study which compared clinician ratings of adherence to electronic pill monitors) or (2) evaluated an interventional system which periodically assessed participant adherence as *part of the intervention*, not merely a *study endpoint* (eg, a mobile phone app which notifies clinicians in real time of nonadherence events and encourages them to intervene would count as a "data collection" intervention, but an RCT which evaluated the effects of a psychoeducational program on adherence using electronic pill monitors merely as an *endpoint* would not fall under this category).


### Synthesis

For this scoping review, we performed a qualitative synthesis of the included studies. We categorized the studies by study type, intervention type, population studied, and technological modality. We created a hierarchical taxonomy of intervention components.

## Results

### Study Selection and Extraction


The literature search identified 21,749 results. A search of related reviews and references in relevant articles did not find any additional results. Of these, 3955 duplicates were removed, and 17,542 results were excluded based on the title and abstract, yielding 252 results (Cohen kappa before reconciliation=0.82, 95% CI 0.78-0.86). These were screened based on their full texts, and 125 were excluded (Cohen kappa before reconciliation=0.80, 95% CI 0.72-0.87). This left a total of 127 articles and conference proceedings that met the inclusion criteria (Figure 1). In the final rerun of the search in September 2018, 3 indexed manuscripts were found that replaced conference proceedings describing the same studies. All included studies are provided in [Multimedia Appendix 2](#).

**Figure 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses Diagram of included studies.


There was an increase over time (2000-2018) in the prevalence of included articles. The graph showing the number of included articles per year is given in [Figure 2](#). As the amount of total published research has also increased over this same time span, we provide in [Figure 3](#), a graph relative to the total amount of

published research in MEDLINE. Each data point is calculated by dividing the number of included articles from a given year by the number of total MEDLINE articles published during that same year (based on MEDLINE's "Publication Date" field).

**Figure 2.** Included articles by year.



**Figure 3.** Included articles by year, divided by total number of MEDLINE articles published during that same year.



### Characteristics of Included Studies

Of the included studies, 40.2% (51/127) were RCTs; 56.7% (72/127) implemented nonrandomized interventions (eg, nonrandomized multiarm studies, single-arm studies, pilot feasibility studies, comparison of multiple measurement methods in 1 group, etc). The remaining 4 [36-39] were surveys or focus groups of potential participants evaluating participant willingness to use specific interventions.

Many psychiatric populations were studied (Figure 4): primary psychotic disorders (n=39), substance use disorders (n=36), major depression (n=20), bipolar disorder (n=9), attention deficit hyperactivity disorder (ADHD; n=2), and PTSD (n=2). Common transdiagnostic populations included “schizophrenia or bipolar disorder” (n=8), dual diagnosis (substance use disorder comorbid with a primary psychiatric disorder, n=3), and pandiagnostic, that is, any psychiatric disorder (n=6). The remaining studies evaluated all patients taking aripiprazole [40] or pooled data from multiple clinical trials of medications for schizophrenia and ADHD [41]. Among the substance use disorders, tobacco


was studied most (n=15), followed by opioids (n=11), alcohol (n=5), cannabis (n=2), amphetamines (n=2), and all substance use disorders (n=1).


Studied outcomes included intervention feasibility (n=29), system usability (n=12), and participant satisfaction or acceptability (n=38). Furthermore, 94 studies included some measure of medication adherence, and 32 evaluated or compared the accuracy of one or more medication adherence measurement methods. Many studies evaluated other outcomes, including change in symptoms over time, reduction in substance use, or physiologic metrics such as sleep duration or step count.

### Synthesis

On the basis of the included articles, we constructed a taxonomy of components of the studied technological systems, broken down into the 2 major categories of “data collection components” and “interventional components.” Note that any particular study or technological system may include components from one or both categories. A concept map of the full taxonomy is provided in Figure 5.

Figure 4. Number of articles by diagnosis. ADHD: attention deficit hyperactivity disorder.



**Figure 5.** Visual concept map of components of studied technological systems. GPS: global positioning system.

## A. Data Collection Components

Adherence measurement and monitoring are critical components of adherence enhancement in many ways, from accurately evaluating the efficacy of interventions designed to improve adherence to identifying patients who would benefit from adherence interventions. The majority of studies collected only adherence data, however, we also included a collection of *related* data within this category (A.9.). This reflects the group of technological systems that collect data other than adherence for downstream use in interventional components.

### A.1. Patient Self-Report

By far, the most commonly studied method ( $n=54$ ) for measuring medication adherence was patient self-report. Many multicomponent apps or websites included daily or weekly surveys filled out by the participants; self-report of medication adherence was frequently included in these surveys [42-48]; IVR, telephone, text messaging, and videoconferencing interventions similarly included questions evaluating medication adherence [49-55]. Furthermore, self-report was frequently used as a baseline adherence assessment method with which other, more objective measures were compared [56-59].

### A.2. Care Network Report

Some studies evaluated the subjective overall adherence report by individuals other than the participant (eg, treating clinicians or participant's friends, family, or other social support). These

reports were not based on direct observation, but rather on subjective, retrospective assessments of a patient's adherence history or an overall perception of their likelihood to be adherent. This method was rarely used; none of the included studies included it as part of an adherence intervention. However, 6 studies evaluated its accuracy compared with other measurement methods [56-58,60-62]. All 6 studies evaluated 1-time subjective clinician rating scales, and 2 also evaluated reports from a "relative" or a "close informant" [58,62].

### A.3. Direct Visualization of Medication Ingestion

Many interventions attempted to confirm adherence by *directly visualizing* the process of medication administration. Although there were many types of direct visualization methods, all of them involved observation of the patient during the process of physically ingesting the medication.

#### A.3.1: Human Observation, Synchronous

Direct visualization of medication ingestion in real time by a human observer was studied in 4 interventions. A total of 2 studies used direct in-person observation as a gold standard to evaluate the accuracy of other measurement systems (A.3.1.1) [63,64], whereas 2 other studies used mobile videoconferencing technology to observe dosing remotely (A.3.1.2) [65,66]. Both of these studies had a standardized protocol for observed dosing, ostensibly to ensure adherence; the participants kept the pill container on camera while removing the medication and showed



their open mouth following pill ingestion to prevent hiding the medication in the cheek.

### **A.3.2. Human Observation, Asynchronous**

A related method of visual adherence measurement, studied by 4 included articles, involved the participant capturing static photos or videos of the medication dosing process, to be evaluated in nonreal time (n=4). One study [38] evaluated the acceptability of static photos of pill counts (A.3.2.1) among a population of patients on buprenorphine. A total of 2 other studies discussed daily photographs of individual medication doses taken at the time of ingestion, either as the only intervention [67] or as part of a multicomponent intervention app [68]. Moreover, 1 study discussed nonreal-time video footage (A.3.2.2) captured on mobile phones as an adherence measurement method [69].

### **A.3.3. Computer Observation (Fully Automated)**

Overall, 2 included studies evaluated the feasibility, usability, and measurement efficacy of AICure (AICure, LLC), an automated form of direct observation using CV algorithms to confirm pill ingestion in real time without a human observer [41,64]. The platform worked by automatically identifying the patient and drug in real-time video footage taken on mobile devices to confirm ingestion.

### **A.4. Biomarkers and Metabolites**

In current clinical practice, measurements of concentrations of medications or medication metabolites in body fluids such as urine or serum are frequently used to assess compliance with the medication. A total of 15 of the included studies either included such measurements as part of a multicomponent intervention [70,71], used serum (A.4.1) or urine (A.4.2) measurements as a gold standard comparator for other adherence measurement approaches [58,64,72], or evaluated a novel system for biological confirmation of adherence. Such systems included measurements from breath (A.4.3) [73,74], oral fluid (A.4.4) [75,76], hair (A.4.5) [77-79], and skin (A.4.6) [80]. Overall, 1 study evaluated the accuracy of urine systems for an experimental cannabinoid [81]. Another study proposed a system of quantitative serum drug monitoring for all psychiatric medications to track adherence and better achieve therapeutic levels [82].

### **A.5. Smart Pill Containers**

“Smart” pill containers using digital information technology to measure adherence (eg, Medication Event Monitoring System [MEMS]) were well-represented among the included studies. Most of these systems used electronic components in the cap to detect the opening of the pill bottle. Data were either wirelessly transmitted to a central server periodically or were retrieved from the bottle at clinic visits. A total of 34 studies directly used such a pill container as part of an intervention or evaluated the accuracy of adherence measurement through such a system [56-62,67,70,71,83-106]. The MEMS was by far the most widely used, but variations on it, including a nasal spray monitor [86], were also used. A total of 19 included studies examined antipsychotic medication adherence, 10 studied substance use disorders, and the remaining 3 studied mood

disorders. Many more studies used the MEMS as the endpoint measure for an adherence-enhancing intervention.

### **A.6. “Smart” or Digital Pill**

A total of 5 studies evaluated the efficacy of a “digital pill” or “digital medicine system” which, upon gastric activation, transmitted a signal to a wearable sensor which then uploaded data to a central server. All of the studies were conducted with antipsychotics meant to be used long term [40,63,107-109].

### **A.7. Pill Counts**

One common low-cost method of medication adherence measurement involved single-time counting of pills remaining in a container, either in-person or remotely over videoconferencing software. Pill counts were used (n=12) either as one component of a multicomponent adherence-enhancing intervention or in comparisons of adherence measurement methods [56-59,66,67,70,71,89,96,104,110]. We did not include studies that merely used pill counts to evaluate a study endpoint.

### **A.8. Drug Utilization Measurements**

Finally, objective measurements such as pharmacy refills (A.8.1) or insurance claims (A.8.2), which do not directly capture medication administration data but may provide indirect indices of medication possession and adherence, have been used to assess adherence behaviors over the long term (n=3). Overall, 2 studies calculated medication possession ratios and used them in feedback interventions to enhance as well as measure adherence: one with antipsychotics [111] and one with PTSD medications [112]. Another study incorporated barcodes attached to pill containers (A.8.3). Participants scanned these codes with their mobile devices upon receiving the pill containers, allowing for another form of pickup-level verification [68]. Pill count (eg, observing how many pills were left in the container) was another commonly (n=12) used component either in multicomponent adherence-enhancing interventions or in comparisons of adherence-monitoring methods.

### **A.9. Collection of Adherence-Related Data**

It was common (n=46) for interventions to collect and track adherence-related data other than medication adherence itself (eg, symptoms and health care utilization) for a variety of downstream uses. As with adherence measurement, we excluded interventions that tracked other data for the purposes of evaluating study endpoints but did not *use* the data in the intervention itself. Data collection modalities included mobile apps, Web forms, phone calls, IVR, one-way text messages, and smart pill dispensers [90]. Most of the data were used in clinician monitoring or alert systems, but some were used to tailor patient-specific motivational therapy (eg, in handling specific drug use triggers in substance use disorders) [113,114]. By far, the most commonly collected data were basic psychiatric symptom assessments (A.9.1), for example, early warning signs of psychosis [105], illicit drug cravings [115], withdrawal symptoms [70,90], mood [107,116], or PTSD symptoms [112]. Other studies tracked attitudes toward medication [117] or medication side effects [118,119] to guide motivational interventions (A.9.2). Others tracked potential triggers or indices for relapse likelihood including stress, anxiety, sleep, and social support [42,44,120]. Some tracked health care utilization

metrics, such as primary care visits attended, specialty care referrals followed, and medication changes made (A.9.3) [121,122]. A total of 3 studies [42,116,123] collected real-time global positioning system information through mobile phones (A.9.4); in one of the studies, redirection alerts were provided when patients entered previously assigned high-risk areas [123]. Some studies allowed for free text entry by the participant in the form of online journals which could later be viewed and correlated with adherence and symptomatic data (A.9.5) [42,47].

## B. Adherence-Enhancing Interventions

Any technological component not designed directly to improve medication adherence monitoring accuracy was classified as an “adherence-enhancing” intervention. Generally speaking, these components were designed to enhance a participant’s motivation (eg, motivational intervention or psychoeducation) or ability (eg, reminders or social support engagement) to adhere to pharmacologic therapy.

### B.1. Reminders

Reminders directed participants to take their medication as prescribed (n=25). Most of these studies (n=14) used short messaging service (SMS) messages sent to a participant’s mobile phone [36,37,39,54,87,124-132]. Usually, these were prespecified reminder messages programmed to be sent at specific times, but some studies examined the use of personalized SMS reminder messages sent by another person, either a “treatment partner” from the community [36] or a social worker [54]. Other messages included reminders delivered as programmatic app notifications, which functioned similarly to SMS reminders [43,52,68,91,118] and often comprised one aspect of multicomponent app interventions. Still other interventions used smart pill containers as the vehicle for reminder delivery—one smart dispenser uses visual and sound alarms to alert the participant when it is time to take medication [95,98], and another similarly uses audio alarms which can be silenced by pressing a button on the pill dispenser [96,105]. Email [45] and an unspecified social media reminder [133] have also been used.

### B.2. Supportive Messages

Some interventions (n=21) included supportive one-way messages delivered through SMS, IVR, telephone call, or mobile app, which encouraged or motivated the participant. Some used inspirational quotes such as “The journey of a thousand miles starts with a single step” [49], whereas others displayed the length of successful adherence [68], encouraged continued engagement with the platform [113], or provided encouraging health facts, for example, “Today your blood pressure has been reduced to that of a nonsmoker” [134]. Most were generated and sent or displayed automatically [37,114,123,127,133,135-137], but others were sent as part of a standardized protocol by care team members [53] or lay health support persons [138], or in response to specific behaviors such as persistently elevated adherence [54,118,139] or positive responses to therapeutic questions [55]. Automated relational agents performed this behavior as part of a larger conversation [140,141]. One focus-grouping study found that participants would like to receive personalized self-efficacy messages [39].

## B.3. Social Enhancement Interventions

This general category focused on leveraging existing social support or building new social support networks for participants.

### B.3.1. Engaging Existing Social Support

Technological interventions focused on engaging patients’ social support systems (friends, family, etc) in their care were prevalent (n=9). One study focus-grouped an intervention involving a lay “treatment partner” sending SMS antipsychotic adherence reminders to keep the participant engaged in care [36]. Another study used an online social network intervention to allow former smokers to support current smokers in adhering to their nicotine replacement therapy and promoting cessation [142]. An automated “conversational agent” encouraged participants in a study of individuals with schizophrenia to recruit a specific member of their social network to provide reminders and logistical support (eg, transportation problems) and later referenced this social support in future conversations [140], whereas a telephone and Web-based intervention encouraged participants to find and contact social supports [142]. Other interventions incorporated a lay health supporter as a *recipient* of other technological interventions such as psychoeducation [143] or adherence reminder systems and data-gathering surveys [125]. Still others [125,138,144,145] looped social support into the intervention by sending them automated periodic progress reports on adherence and symptomatic control and encouraging the social support to reach out to the participant depending on the gathered data. One study allowed participants to choose weekly support phone calls with a family member or friend [145] versus a trained peer support specialist and compared outcomes.

### B.3.2. Building New Social Support

A total of 6 studies focused instead on building new social support structures for participants. All 6 included online discussion forums or groups where participants could discuss a variety of treatment or adherence-related issues [42,47,123,142,146,147], and all were part of multicomponent interventions. One study [142] included a complete social network of former and current smokers with member profiles and private messaging in addition to public forum posts.

### B.3.3. Relational Agent

A total of 2 studies evaluated the use of “embodied relational agents” as adherence aids [140,141] in schizophrenia treatment. These relational agents were computer-generated animated humanoid figures who interacted through scripted modules and programmed response trees, allowing for limited bidirectional communication with the participant. The included studies that evaluated relational agents used the agents as a general purpose treatment delivery modality, incorporating psychoeducation, adherence measurement, symptom assessment, behavioral counseling, encouragement, and general purpose social support.

## B.4. Facilitating Care Team Access

Some adherence interventions (n=13), in particular mobile phone and Web apps, included functionality for the participant to initiate contact with a care team representative at any time. Some [118] allowed the sending of prespecified messages regarding side effects or symptoms or had the study staff screen messages

meant for the clinical care team [128,129], whereas others allowed for general purpose two-way messaging through SMS, email, or a messaging system designed separately for the app [42,45,53,65,114,139,147]. Another stored care team contact information within a multicomponent app to enable one-button contact, and displayed this button based on certain user responses [68]. One study collecting adherence data via IVR allowed participants to be transferred to a case manager during the IVR call [148], and another evaluating text message content preferences among potential participants receiving buprenorphine maintenance treatment found that they would prefer frequent provider contact to be available [39].

### **B.5. Data Feedback**

This component of interventions was designed to present collected data on medication adherence or adherence-related data to users of the system, including participants, clinicians, or both. Participant feedback was designed to enhance self-knowledge and accountability, whereas clinician feedback enabled monitoring of patient adherence, as well as early and targeted intervention in the case of nonadherence or other treatment concerns.

#### **B.5.1. Patient-Directed Feedback**

Medication adherence feedback directed toward patients was used in 25 studies. This category included any intervention component which enabled the participant to view their own adherence data, either in real time through a mobile phone or website interface or via periodically generated reports. Frequently, this was one part of multicomponent interventions, but some studies evaluated the effect of feedback alone as an adherence-enhancing intervention [84,85,88,102,103]. Other systems included feedback on more than just adherence data (eg, symptomatic progression as assessed by self-report) [44,46,120]. Note that accurate medication adherence feedback rests on the assumption of an accurate measurement method.

#### **B.5.2. Clinician-Directed Feedback**

Various systems were developed to keep treating clinicians informed about medication adherence and other related data, to enable earlier and more accurate identification of potential issues for intervention. The data given to the clinician was sourced from many of the previously listed medication measurement components (direct visualization, smart pill dispenser, self-report, etc). Multiple studies (n=31) explicitly mentioned such systems [40,42,44-46,49,51,53,63,65,91,93,95,104,105,107,108,111,112,114,116,118-120,123,125,138,139,144,145,147], which fell under 3 major categories (not mutually exclusive): “portal” real-time monitoring (n=15), periodic reporting (n=9), and alerts (n=16). Real-time monitoring (B.5.2.1) allows the clinician to, at any time they choose, examine their participants’ medication adherence data, almost always through Web portals [40,44-46,63,65,95,104,105,107,108,116,118,120,147]. Periodic reporting (B.5.2.2) involves standard adherence reports sent at regular intervals, most often through emails [49,51,91,93,111,125,139,144,145]. Alerts (B.5.2.3) are “push” notifications sent to notify clinicians in circumstances that require immediate response, such as suicidal ideation, hospitalization, and life disturbances such as housing eviction, physical side effects (eg, chest pain), or relapse to drug use [42,44,51,53,65,104,

105,108,111,112,114,119,123,138,144,145]. In some studies, patients’ social support as well as the clinical care team was able to receive reports or alerts [53,125,138,144,145].

### **B.6. Passive Education**

Educational interventions were present in 39 included studies [42,45,47,51,64,68,70,71,84,88,91,93,102,105,113,114,118,123,127,130,134,136,137,139-142,146-157]. Modalities included websites, mobile apps, telephone calls, SMS messages, IVR calls, relational agents, and smart pill dispensers. Frequently presented educational topics included the studied disorder (eg, chronicity, symptom management, triggers, and warning signs), the studied medications (eg, purpose, onset of action, and possible side effects), strategies to improve medication adherence (eg, routines and planning for potential barriers), the importance of medication adherence, coping strategies for setbacks, and the importance of social support. In the vast majority of studies, education was one component of a multicomponent intervention.

### **B.7. Comprehensive Mental Health Care**

Many studies (n=22) evaluated medication adherence in the context of remotely delivered psychiatric or mental health care—defined for the purposes of this study as when normal components of mental health care visits (cognitive behavioral therapy [CBT], symptomatic check-ins, and medication adherence counseling) were delivered remotely, through phone calls or videoconferences, by members of the care team including psychiatrists, nurses, pharmacists, and specialized coaches. Some of the studies compared medication adherence (and other outcomes) between telecare and care as usual [158-161], whereas others evaluated the effects on adherence of novel standardized intervention protocols delivered over telephone or videoconference [50,53,65,96,112,115,119,122,127,143,146,149,152,154-157,162]. The content of novel protocols varied widely, but frequently focused on disease or medication education, symptomatic assessment, and motivational enhancement around medication adherence. Overall, 6 explicitly referenced motivational interviewing [65,112,127,146,149,156] and 3 drew from CBT [127,143,149]. Frequency ranged from daily to monthly. Some were part of multicomponent technological interventions [65,96].

### **B.8. Adherence-Targeted Interactive Psychotherapy or Counseling**

Some interventions used technology to deliver adherence-focused psychotherapy or counseling, either remotely as part of remote care or as part of a standardized intervention delivered through an app or a website. One major modality which emerged was motivational intervention around medication adherence (n=9). This was used in remote psychiatric care in the aforementioned 6 studies [65,112,127,146,149,156], but it was also used without a human clinician in 3 mobile phone apps or Web-based interventions [42,47,118]. In one study, the patient was queried about their reasons for nonadherence and, based on the reasons, was provided with tailored motivational feedback [118]. In the others, the cost-benefit framework was used within the website to encourage the participant to evaluate strategies, solve problems, and set goals [42,47]. The other major

framework which emerged (n=12) was CBT, which is used as a major component of psychotherapy in many of the studied disorders and can help restructure maladaptive thoughts about psychoactive medication. In the included studies, strategies from CBT were used as part of tele-mental health care [127,143,149], as the comparator [84], or as part of Web or mobile phone app-delivered curricula [42,45,47,123,134,136,137]. Another study used CBT strategies in a tailored text messaging intervention to probe for unhelpful behaviors or thought patterns, using information collected from the patient [55].

### B.9. Secure Medication Storage

Some studies used a “security” component designed to prevent overuse or diversion, or prevent theft, of medication (n=3). All 3 of these studies were in opioid use disorder populations receiving buprenorphine [65,70,71] and used a secure locked pill dispenser. In 2 studies, doses were only available during a 3-hour window each day and were taken under the supervision of a nurse. In one study, the dispenser released a daily dose of medication via an access code transmitted during a remote check-in with a mobile recovery coach [65].

### B.10. Contingency Management

Finally, some studies (n=6) included a contingency management or incentive system which involved prizes or rewards [67-69,

93,118,125]. We did not count studies as having a “contingency management” component if the payment or rewards were given merely for study participation; the incentives had to be built into the overall system and specifically incentivize adherence behaviors or comply with adherence-monitoring protocols. Most of these systems took the form of virtual points which were earned based on specific behaviors, tracked through mobile or Web apps, and could be redeemed for cash. In 3 of these, points were earned for scanning a barcode or sending photos or videos for adherence monitoring purposes [67-69], whereas others were earned by completing education materials, responding to messages, or checking in to adherence enhancement systems [93,118,125].

### Multicomponent Interventions

Multicomponent interventions were those that used multiple intervention components in tandem. Below are tables (Tables 1-4) for the 4 most common disorder contexts (substance use disorder, depression, schizophrenia spectrum, and bipolar disorder) which show the multicomponent apps with at least 4 separate components. We use our framework to categorize and decompose the interventions based on which components they include.

**Table 1.** Comparison of multicomponent interventions for schizophrenia spectrum disorders with 4 or more components, by presence or absence of particular components.

Source	System components <sup>a</sup>												
	A.1-8	A.9	B.1	B.2	B.3	B.4	B.5.1	B.5.2	B.6	B.7	B.8	B.9	B.10
Aschbrenner (2016) [54]	✓ <sup>b</sup>	✓	✓	✓	— <sup>c</sup>	—	—	—	—	—	—	—	—
Beebe (2014) [50]	✓	✓	—	—	—	—	—	—	—	✓	✓	—	—
Ben-Zeev (2014) [139]	✓	—	—	✓	—	✓	—	✓	✓	—	—	—	—
Bickmore (2010) [140]	✓	—	—	✓	✓	—	✓	—	✓	—	—	—	—
Granholm (2012) [55]	✓	✓	—	✓	—	—	—	—	—	—	✓	—	—
Kane (2013) [63]	✓	✓	—	—	—	—	✓	✓	—	—	—	—	—
Kreyenbuhl (2016) [12]	✓	✓	✓	✓	—	✓	✓	✓	✓	—	✓	—	✓
Ruskin (2003) [105]	✓	✓	✓	—	—	—	—	✓	✓	—	—	—	—
Stentzel (2016) [53]	✓	✓	—	✓	—	✓	—	✓	—	✓	—	—	—
Xu (2016) [125]	—	✓	✓	—	✓	—	—	✓	—	—	—	—	✓

<sup>a</sup>A.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions. B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.

<sup>b</sup>✓: Component is present.

<sup>c</sup>—: Component is not present.

**Table 2.** List of multicomponent interventions for bipolar disorder with 4 or more components, by presence or absence of particular components.

Source	System component <sup>a</sup>												
	A.1-8	A.9	B.1	B.2	B.3	B.4	B.5.1	B.5.2	B.6	B.7	B.8	B.9	B.10
Faurholt-Jepsen (2014) [44]	✓ <sup>b</sup>	✓	— <sup>c</sup>	—	—	—	✓	✓	—	—	—	—	—
Lauder (2017) [42]	✓	✓	—	—	✓	✓	✓	✓	✓	—	✓	—	—
Sajatovic (2015) [93]	✓	—	—	—	—	—	✓	✓	✓	—	—	—	✓
Wenze (2014) [136]	✓	✓	—	✓	—	—	—	—	✓	—	✓	—	—

<sup>a</sup>A.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions. B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.

<sup>b</sup>✓: component is present.

<sup>c</sup>—: component is not present.

**Table 3.** Comparison of multicomponent interventions for substance use disorder with 4 or more components, by presence or absence of particular components.

Source	System component <sup>a</sup>												
	A.1-8	A.9	B.1	B.2	B.3	B.4	B.5.1	B.5.2	B.6	B.7	B.8	B.9	B.10
Gordon (2017) [68]	✓ <sup>b</sup>	✓	✓	✓	— <sup>c</sup>	✓	✓	—	✓	—	—	—	✓
Gustafson (2016) [123]	—	✓	—	✓	✓	—	✓	✓	✓	—	✓	—	—
McClure (2016) [114]	—	✓	—	✓	—	✓	—	✓	✓	—	—	—	—
Mooney (2007) [84]	✓	—	—	—	—	—	✓	—	✓	—	✓	—	—
Schuman-Olivier (2018) [65]	✓	✓	—	—	—	✓	—	✓	—	—	✓	✓	—
Sigmon (2015) [71]	✓	✓	—	—	—	—	—	—	✓	—	—	✓	—
Swan (2012) [146]	—	✓	—	—	✓	—	✓	—	✓	✓	✓	—	—
Tseng (2017) [127]	—	—	✓	✓	—	—	—	—	✓	✓	✓	—	—

<sup>a</sup>A.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions. B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.

<sup>b</sup>✓: component is present

<sup>c</sup>—: component is not present.

**Table 4.** Comparison of multicomponent interventions for major depressive disorder with 4 or more components, by presence or absence of particular components.

Source	System component <sup>a</sup>												
	A.1-8	A.9	B.1	B.2	B.3	B.4	B.5.1	B.5.2	B.6	B.7	B.8	B.9	B.10
Aikens (2015) [138]	✓ <sup>b</sup>	✓	— <sup>c</sup>	✓	✓	—	—	✓	—	—	—	—	—
Fortney (2007) [157]	✓	✓	—	—	—	—	—	—	✓	✓	—	—	—
Gervasoni (2010) [119]	✓	✓	—	—	—	—	—	✓	—	✓	✓	—	—
Lauritsen (2017) [46]	✓	✓	—	—	—	—	✓	✓	—	—	—	—	—
Meglic (2012) [147]	—	✓	—	—	✓	✓	✓	✓	✓	—	—	—	—
Mohr (2015) [91]	✓	✓	✓	—	—	—	✓	✓	✓	—	—	—	—
Pfeiffer (2017) [145]	✓	✓	—	—	✓	—	—	✓	—	—	—	—	—
Piette (2013) [144]	✓	✓	—	—	✓	—	—	✓	—	—	—	—	—
Rickles (2005) [152]	✓	✓	—	—	—	—	—	—	✓	✓	—	—	—
Robertson (2006) [45]	✓	✓	✓	—	—	✓	✓	✓	✓	—	✓	—	—
Rusche-Skolarus (2015) [51]	✓	✓	—	—	—	—	—	✓	✓	—	—	—	—

<sup>a</sup>A.1-8: Adherence data collection. A.9: Collection of related data. B.1: Adherence reminders. B.2: Supportive messages. B.3: Social network interventions. B.4: Facilitating care team contact. B.5.1: Data feedback to patient. B.5.2: Data feedback to clinician. B.6: Education. B.7: Comprehensive mental health care. B.8: Adherence-targeted psychotherapy. B.9: Secure medication storage. B.10: Contingency management.

<sup>b</sup>✓: component is present.

<sup>c</sup>—: component is not present.

## Discussion

### Principal Findings

Our study is the first to create a literature-driven taxonomy of the components of adherence-monitoring methods and adherence-enhancing interventions used across adult psychiatric disorders. There is a proliferation of frameworks used to discuss these technological interventions, some of which are borrowed from nonpsychiatric adherence studies. We hope that this study will build on existing frameworks to provide a definitive framework for this specific context; in particular, we hope to capture the breadth of studied interventions, and provide a uniform vocabulary with which to discuss and compare them. This taxonomy may prove useful during the design phase of a new intervention, where investigators or clinicians may choose to include relevant components from the framework to suit their population or outcome of interest.

Although the framework was constructed bottom-up from the literature, it does ultimately appear to parallel existing frameworks of nonadherence behaviors. Reminders to take medication primarily address *involuntary* nonadherence concerns, whereas security and monitoring interventions often address *voluntary* nonadherence [20]. Educational interventions often aim to provide information and correct misconceptions about disorders, medications, and side effects (addressing *perceptual* nonadherence factors), whereas supportive interventions such as social support engagement and online community building attempt to address the well-studied association between perceived social support and medication nonadherence [163]. It is perhaps not surprising that adherence interventions parallel perceived causes of nonadherence, but it is reassuring nonetheless.

Many of the intervention types have been delivered using various *modalities*. It is useful to draw a distinction between the intervention *type* or *component* (eg, educational, reminder, supportive, feedback, etc) and the *modality* by which it is delivered (SMS, IVR, app, website, etc). Although certain modalities of delivering certain interventions may ultimately prove to have advantages over others (for instance, navigating a mobile app may well be more acceptable than waiting for IVR dialogues when filling out an adherence survey), it is not yet clear from the literature whether this is the case. As technology continues to evolve, there will no doubt be new modalities of intervention delivery (for instance, the once prevalent studies of IVR and telephonic interventions have largely been supplanted in recent years by SMS text messaging, website, and mobile phone app studies). One notable exception: the distinction between *modality* and *intervention type* does not apply to most data collection components (smart pill dispensers, body fluid sampling, and digital pills) as the two are inextricably tied.

The body of literature on this topic is growing, as reflected by the increasing number of studies included from recent years. However, looking at the literature from any individual psychiatric or substance use disorder highlights the fact that the field remains young, and most studies conducted are small-n pilot studies. Furthermore, large RCTs are necessary to elucidate the impact of particular interventions.

We found that most components are used transdiagnostically, that is, they have been studied in schizophrenia spectrum disorders, mood disorders, multiple substance use disorders, and PTSD (ie, most psychiatric disorders which have a pharmacologic component to therapy). Data collection components (including smart pill dispensers, periodic self-report,

and body fluid testing), reminders, educational interventions, tele-health-driven counseling, and multicomponent disease management apps have been explored in most or all psychiatric disorders. This suggests that despite the differences in the mental state between different disorders, and perhaps even different primary reasons for nonadherence, there is still much to be learned and transferred from one domain to the others. Particularly, when designing a new intervention for clinical or research use, investigators would do well to peruse the literature from different psychiatric disorders for ideas and related work. It is possible that transdiagnostic interventions (perhaps with disorder-specific education or support modules) might ultimately improve medication adherence in a general psychiatric population. However, as of yet, very little transdiagnostic research has been conducted in this field.

Multicomponent interventions, including comprehensive disease management apps, have been studied in the majority of psychiatric disorders. These interventions present a challenge from a research standpoint, as it is difficult to assess the impact of any individual component without large, factorial-design studies. However, there may be synergistic adherence effects from comprehensive disease management apps, in the same way that standard psychiatric care visits address a wide variety of adherence concerns and motivational factors. Furthermore, if these interventions are to one day be used regularly in clinical practice, multicomponent interventions are more practical from an implementation standpoint.

One surprising fact is that many studies which evaluated the effect of adherence-enhancing interventions used *self-reported* adherence, or adherence as measured by a smart pill dispenser, as the endpoint. Studies have shown that self-reported adherence frequently overestimates true adherence [58,65,164,165]; this fact may compromise or blur results from many of these studies.

Biological measurements and directly observed ingestion provide far better adherence assessment, but are costly, inconvenient, and often impractical to implement. Novel adherence measurement systems, such as digital pills, automated adherence monitoring, and remote direct observation, may ultimately provide a better compromise between accuracy and practicality in future trials. In fact, some of these novel methods have been evaluated and used in clinical trials already. Accurate assessment of adherence is crucial to evaluating the efficacy of any of these interventions, and future investigators would do well to select their adherence measurement endpoint wisely.

### Strengths and Limitations

The strengths of our study include the breadth of the topic area and the comprehensive coverage of all types of interventions, as well as the literature-guided taxonomic framework. Our tables of multicomponent interventions further show the utility of this transdiagnostic framework to decompose and categorize interventions across all adult mental health and substance use disorders. However, our study is limited by this same breadth; we were unable to conduct a quantitative synthesis or formal meta-analysis of all included studies given the wide variety of interventions, populations, and outcomes. In the future, we plan to build off of this study and conduct more focused comparisons of specific topic areas.

### Conclusions

In conclusion, we provide a systematic review of the literature on technological interventions for medication adherence and monitoring in mental health and substance use disorders; we then use the included studies to develop a literature-driven transdiagnostic framework of intervention components. We hope this will help guide future research in the field and ultimately lead to further clinical applications.

---

### Acknowledgments

The preparation of this study was partially supported by a P30 Center of Excellence grant from the National Institute on Drug Abuse (National Institutes of Health) P30DA029926 (Principal Investigator: LAM) and R34DA040086 (Principal Investigator: ZS-O).

---

### Conflicts of Interest

JMS, JTB, ZS-O, and LAM are affiliated with MySafeRx, a nonprofit organization that supports the development, implementation, and dissemination of technological solutions for medication adherence in mental health and substance use disorder treatment. From 2017 to 2018, JMS received a salary as a software developer for MySafeRx. No other conflicts of interest are declared.

---

### Multimedia Appendix 1

Search strategies for included databases.

[[PDF File \(Adobe PDF File\), 78KB - mental\\_v6i3e12493\\_app1.pdf](#)]

---

### Multimedia Appendix 2

Details of included studies.

[[XLSX File \(Microsoft Excel File\), 129KB - mental\\_v6i3e12493\\_app2.xlsx](#)]

---

### References

1. Witt K, van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. *PLoS One* 2013;8(2):e55942 [FREE Full text] [doi: [10.1371/journal.pone.0055942](https://doi.org/10.1371/journal.pone.0055942)] [Medline: [23418482](https://pubmed.ncbi.nlm.nih.gov/23418482/)]
2. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, de Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. *Ther Adv Psychopharmacol* 2013 Aug;3(4):200-218 [FREE Full text] [doi: [10.1177/2045125312474019](https://doi.org/10.1177/2045125312474019)] [Medline: [24167693](https://pubmed.ncbi.nlm.nih.gov/24167693/)]
3. Cullen BA, McGinty EE, Zhang Y, Dosreis SC, Steinwachs DM, Guallar E, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. *Schizophr Bull* 2013 Sep;39(5):1159-1168 [FREE Full text] [doi: [10.1093/schbul/sbs097](https://doi.org/10.1093/schbul/sbs097)] [Medline: [23112292](https://pubmed.ncbi.nlm.nih.gov/23112292/)]
4. Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. *Bipolar Disord* 2006 Oct;8(5 Pt 2):618-624. [doi: [10.1111/j.1399-5618.2006.00368.x](https://doi.org/10.1111/j.1399-5618.2006.00368.x)] [Medline: [17042834](https://pubmed.ncbi.nlm.nih.gov/17042834/)]
5. Meyers BS, Sirey JA, Bruce M, Hamilton M, Raue P, Friedman SJ, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. *Arch Gen Psychiatry* 2002 Aug;59(8):729-735. [Medline: [12150649](https://pubmed.ncbi.nlm.nih.gov/12150649/)]
6. Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. *Addict Behav* 2012 Sep;37(9):1046-1053 [FREE Full text] [doi: [10.1016/j.addbeh.2012.04.011](https://doi.org/10.1016/j.addbeh.2012.04.011)] [Medline: [22626890](https://pubmed.ncbi.nlm.nih.gov/22626890/)]
7. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. *Addiction* 2003 May;98(5):673-684. [Medline: [12751985](https://pubmed.ncbi.nlm.nih.gov/12751985/)]
8. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. *Drug Alcohol Depend* 2008 Apr 01;94(1-3):151-157. [doi: [10.1016/j.drugalcdep.2007.11.003](https://doi.org/10.1016/j.drugalcdep.2007.11.003)] [Medline: [18155364](https://pubmed.ncbi.nlm.nih.gov/18155364/)]
9. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. *Patient Relat Outcome Meas* 2014;5:43-62 [FREE Full text] [doi: [10.2147/PROM.S42735](https://doi.org/10.2147/PROM.S42735)] [Medline: [25061342](https://pubmed.ncbi.nlm.nih.gov/25061342/)]
10. Stein-Shvachman I, Karpas DS, Werner P. Depression treatment non-adherence and its psychosocial predictors: differences between young and older adults? *Aging Dis* 2013 Sep 20;4(6):329-336 [FREE Full text] [doi: [10.14336/AD.2013.0400329](https://doi.org/10.14336/AD.2013.0400329)] [Medline: [24307966](https://pubmed.ncbi.nlm.nih.gov/24307966/)]
11. Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. *Psychiatr Serv* 2006 May;57(5):673-680. [doi: [10.1176/ps.2006.57.5.673](https://doi.org/10.1176/ps.2006.57.5.673)] [Medline: [16675762](https://pubmed.ncbi.nlm.nih.gov/16675762/)]
12. Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. *J Subst Abuse Treat* 2014 Apr;46(4):456-462. [doi: [10.1016/j.jsat.2013.10.014](https://doi.org/10.1016/j.jsat.2013.10.014)] [Medline: [24332511](https://pubmed.ncbi.nlm.nih.gov/24332511/)]
13. Shiovitz TM, Bain EE, McCann DJ, Skolnick P, Laughren T, Hanina A, et al. Mitigating the effects of nonadherence in clinical trials. *J Clin Pharmacol* 2016 Sep;56(9):1151-1164 [FREE Full text] [doi: [10.1002/jcph.689](https://doi.org/10.1002/jcph.689)] [Medline: [26634893](https://pubmed.ncbi.nlm.nih.gov/26634893/)]
14. Czobor P, Skolnick P. The secrets of a successful clinical trial: compliance, compliance, and compliance. *Mol Interv* 2011 Apr;11(2):107-110 [FREE Full text] [doi: [10.1124/mi.11.2.8](https://doi.org/10.1124/mi.11.2.8)] [Medline: [21540470](https://pubmed.ncbi.nlm.nih.gov/21540470/)]
15. Kronish IM, Moise N. In search of a "Magic Pill" for medication nonadherence. *JAMA Intern Med* 2017 Dec 1;177(5):631-632. [doi: [10.1001/jamainternmed.2016.9658](https://doi.org/10.1001/jamainternmed.2016.9658)] [Medline: [28241306](https://pubmed.ncbi.nlm.nih.gov/28241306/)]
16. Sabaté E. World Health Organization. 2003. Adherence to Long-Term Therapies: Evidence for Action URL: [http://www.who.int/chp/knowledge/publications/adherence\\_report/en/](http://www.who.int/chp/knowledge/publications/adherence_report/en/) [WebCite Cache ID 7379gHG1y]
17. Chapman SC, Horne R. Medication nonadherence and psychiatry. *Curr Opin Psychiatry* 2013 Sep;26(5):446-452 [FREE Full text] [doi: [10.1097/YCO.0b013e3283642da4](https://doi.org/10.1097/YCO.0b013e3283642da4)] [Medline: [23880592](https://pubmed.ncbi.nlm.nih.gov/23880592/)]
18. Farooq S, Naeem F. Tackling nonadherence in psychiatric disorders: current opinion. *Neuropsychiatr Dis Treat* 2014;10:1069-1077 [FREE Full text] [doi: [10.2147/NDT.S40777](https://doi.org/10.2147/NDT.S40777)] [Medline: [24966677](https://pubmed.ncbi.nlm.nih.gov/24966677/)]
19. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. *Acta Psychiatr Scand* 2013 Jan;127(1):23-33. [doi: [10.1111/j.1600-0447.2012.01911.x](https://doi.org/10.1111/j.1600-0447.2012.01911.x)] [Medline: [22900964](https://pubmed.ncbi.nlm.nih.gov/22900964/)]
20. Taggart WL, Shaffer JA, Edmondson D, Bring R, Brondolo E, Falzon L, et al. Posttraumatic stress disorder and nonadherence to medications prescribed for chronic medical conditions: A meta-analysis. *J Psychiatr Res* 2018 Jul;102:102-109. [doi: [10.1016/j.jpsychires.2018.02.013](https://doi.org/10.1016/j.jpsychires.2018.02.013)] [Medline: [29631190](https://pubmed.ncbi.nlm.nih.gov/29631190/)]
21. Grenard JL, Munjas BA, Adams JL, Suttrop M, Maglione M, McGlynn EA, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. *J Gen Intern Med* 2011 Oct;26(10):1175-1182 [FREE Full text] [doi: [10.1007/s11606-011-1704-y](https://doi.org/10.1007/s11606-011-1704-y)] [Medline: [21533823](https://pubmed.ncbi.nlm.nih.gov/21533823/)]
22. Egede LE, Osborn CY. Role of motivation in the relationship between depression, self-care, and glycemic control in adults with type 2 diabetes. *Diabetes Educ* 2010;36(2):276-283 [FREE Full text] [doi: [10.1177/0145721710361389](https://doi.org/10.1177/0145721710361389)] [Medline: [20179250](https://pubmed.ncbi.nlm.nih.gov/20179250/)]
23. Bautista LE, Vera-Cala LM, Colombo C, Smith P. Symptoms of depression and anxiety and adherence to antihypertensive medication. *Am J Hypertens* 2012 Apr;25(4):505-511 [FREE Full text] [doi: [10.1038/ajh.2011.256](https://doi.org/10.1038/ajh.2011.256)] [Medline: [22258334](https://pubmed.ncbi.nlm.nih.gov/22258334/)]



24. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* 2000 Jul 24;160(14):2101-2107. [doi: [10.1001/archinte.160.14.2101](https://doi.org/10.1001/archinte.160.14.2101)] [Medline: [10904452](https://pubmed.ncbi.nlm.nih.gov/10904452/)]
25. Livingston JD, Boyd JE. Correlates and consequences of internalized stigma for people living with mental illness: a systematic review and meta-analysis. *Soc Sci Med* 2010 Dec;71(12):2150-2161. [doi: [10.1016/j.socscimed.2010.09.030](https://doi.org/10.1016/j.socscimed.2010.09.030)] [Medline: [21051128](https://pubmed.ncbi.nlm.nih.gov/21051128/)]
26. Badawy SM, Kuhns LM. Economic evaluation of text-messaging and smartphone-based interventions to improve medication adherence in adolescents with chronic health conditions: a systematic review. *JMIR Mhealth Uhealth* 2016 Oct 25;4(4):e121 [FREE Full text] [doi: [10.2196/mhealth.6425](https://doi.org/10.2196/mhealth.6425)] [Medline: [27780795](https://pubmed.ncbi.nlm.nih.gov/27780795/)]
27. Rootes-Murdy K, Glazer KL, van Wert MJ, Mondimore FM, Zandi PP. Mobile technology for medication adherence in people with mood disorders: a systematic review. *J Affect Disord* 2018 Dec;227:613-617. [doi: [10.1016/j.jad.2017.11.022](https://doi.org/10.1016/j.jad.2017.11.022)] [Medline: [29172054](https://pubmed.ncbi.nlm.nih.gov/29172054/)]
28. Barkhof E, Meijer CJ, de Sonnevile LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade. *Eur Psychiatry* 2012 Jan;27(1):9-18 [FREE Full text] [doi: [10.1016/j.eurpsy.2011.02.005](https://doi.org/10.1016/j.eurpsy.2011.02.005)] [Medline: [21561742](https://pubmed.ncbi.nlm.nih.gov/21561742/)]
29. Killikelly C, He Z, Reeder C, Wykes T. Improving adherence to web-based and mobile technologies for people with psychosis: systematic review of new potential predictors of adherence. *JMIR Mhealth Uhealth* 2017 Jul 20;5(7):e94 [FREE Full text] [doi: [10.2196/mhealth.7088](https://doi.org/10.2196/mhealth.7088)] [Medline: [28729235](https://pubmed.ncbi.nlm.nih.gov/28729235/)]
30. Marsch LA, Carroll KM, Kiluk BD. Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. *J Subst Abuse Treat* 2014 Jan;46(1):1-4 [FREE Full text] [doi: [10.1016/j.jsat.2013.08.010](https://doi.org/10.1016/j.jsat.2013.08.010)] [Medline: [24041749](https://pubmed.ncbi.nlm.nih.gov/24041749/)]
31. Kauppi K, Välimäki M, Hätönen HM, Kuosmanen LM, Warwick-Smith K, Adams CE. Information and communication technology based prompting for treatment compliance for people with serious mental illness. *Cochrane Database Syst Rev* 2014 Jun 17(6):CD009960. [doi: [10.1002/14651858.CD009960.pub2](https://doi.org/10.1002/14651858.CD009960.pub2)] [Medline: [24934254](https://pubmed.ncbi.nlm.nih.gov/24934254/)]
32. Swift R, Oslin DW, Alexander M, Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. *J Stud Alcohol Drugs* 2011 Nov;72(6):1012-1018. [Medline: [22051215](https://pubmed.ncbi.nlm.nih.gov/22051215/)]
33. Välimäki M, Hätönen HM, Lahti ME, Kurki M, Hottinen A, Metsäranta K, et al. Virtual reality for treatment compliance for people with serious mental illness. *Cochrane Database Syst Rev* 2014(10):CD009928. [doi: [10.1002/14651858.CD009928.pub2](https://doi.org/10.1002/14651858.CD009928.pub2)] [Medline: [25300174](https://pubmed.ncbi.nlm.nih.gov/25300174/)]
34. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. *AMIA Annu Symp Proc* 2006:359-363 [FREE Full text] [Medline: [17238363](https://pubmed.ncbi.nlm.nih.gov/17238363/)]
35. Covidence. Melbourne, Australia: Veritas Health Innovation URL: <https://www.covidence.org/home> [accessed 2018-09-25] [WebCite Cache ID 72hcwuKyg]
36. Mall S, Sibeko G, Temmingh H, Stein DJ, Milligan P, Lund C. Using a treatment partner and text messaging to improve adherence to psychotropic medication: a qualitative formative study of service users and caregivers in Cape Town, South Africa. *Afr J Psychiatry (Johannesbg)* 2013 Sep;16(5):364-370. [doi: [10.4314/ajpsy.v16i5.49](https://doi.org/10.4314/ajpsy.v16i5.49)] [Medline: [24051670](https://pubmed.ncbi.nlm.nih.gov/24051670/)]
37. Krebs P, Tseng T, Pham H, Wong S, Sherman SE, Shelley D, et al. Formative evaluation of a text messaging intervention to promote varenicline adherence among tobacco-dependent persons with HIV. *J Health Commun* 2015;20(9):1021-1025. [doi: [10.1080/10810730.2015.1018595](https://doi.org/10.1080/10810730.2015.1018595)] [Medline: [26132516](https://pubmed.ncbi.nlm.nih.gov/26132516/)]
38. Welsh C. Acceptability of the use of cellular telephone and computer pictures/video for "pill counts" in buprenorphine maintenance treatment. *J Opioid Manag* 2016;12(3):217-220. [doi: [10.5055/jom.2016.0334](https://doi.org/10.5055/jom.2016.0334)] [Medline: [27435442](https://pubmed.ncbi.nlm.nih.gov/27435442/)]
39. Tofighi B, Grossman E, Bereket S, D Lee J. Text message content preferences to improve buprenorphine maintenance treatment in primary care. *J Addict Dis* 2016;35(2):92-100. [doi: [10.1080/10550887.2015.1127716](https://doi.org/10.1080/10550887.2015.1127716)] [Medline: [26670868](https://pubmed.ncbi.nlm.nih.gov/26670868/)]
40. Peters-Strickland T, Hatch A, Adenwala A, Atkinson K, Bartfeld B. Human factors evaluation of a novel digital medicine system in psychiatry. *Neuropsychiatr Dis Treat* 2018 Feb;14:553-565 [FREE Full text] [doi: [10.2147/NDT.S157102](https://doi.org/10.2147/NDT.S157102)] [Medline: [29497299](https://pubmed.ncbi.nlm.nih.gov/29497299/)]
41. Shafner L, Hanina A, Kalali A. Using artificial intelligence on mobile devices to measure and maximize medication adherence in CNS trials. 2016 Presented at: ACNP 55th Annual Meeting: Poster Session III; December 4-8, 2016; Hollywood, Florida. [doi: [10.1038/npp.2016.242](https://doi.org/10.1038/npp.2016.242)]
42. Lauder S, Cosgrove VE, Gliddon E, Grimm D, Dodd S, Berk L, et al. Progressing MoodSwings. The upgrade and evaluation of MoodSwings 2.0: an online intervention for bipolar disorder. *Contemp Clin Trials* 2017 Dec;56:18-24 [FREE Full text] [doi: [10.1016/j.cct.2017.02.008](https://doi.org/10.1016/j.cct.2017.02.008)] [Medline: [28257919](https://pubmed.ncbi.nlm.nih.gov/28257919/)]
43. Hammonds T, Rickert K, Goldstein C, Gathright E, Gilmore S, Derflinger B, et al. Adherence to antidepressant medications: a randomized controlled trial of medication reminding in college students. *J Am Coll Health* 2015;63(3):204-208. [doi: [10.1080/07448481.2014.975716](https://doi.org/10.1080/07448481.2014.975716)] [Medline: [25338175](https://pubmed.ncbi.nlm.nih.gov/25338175/)]
44. Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram J, Kessing LV. Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones--the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. *BMC Psychiatry* 2014;14:309 [FREE Full text] [doi: [10.1186/s12888-014-0309-5](https://doi.org/10.1186/s12888-014-0309-5)] [Medline: [25420431](https://pubmed.ncbi.nlm.nih.gov/25420431/)]

45. Robertson L, Smith M, Castle D, Tannenbaum D. Using the internet to enhance the treatment of depression. *Australas Psychiatry* 2006 Dec;14(4):413-417. [doi: [10.1111/j.1440-1665.2006.02315.x](https://doi.org/10.1111/j.1440-1665.2006.02315.x)] [Medline: [17116083](#)]
46. Lauritsen L, Andersen L, Olsson E, Søndergaard SR, Nørregaard LB, Løventoft PK, et al. Usability, acceptability, and adherence to an electronic self-monitoring system in patients with major depression discharged from inpatient wards. *J Med Internet Res* 2017 Dec 21;19(4):e123 [FREE Full text] [doi: [10.2196/jmir.6673](https://doi.org/10.2196/jmir.6673)] [Medline: [28432040](#)]
47. Lauder S, Chester A, Castle D, Dodd S, Gliddon E, Berk L, et al. A randomized head to head trial of MoodSwings.net.au: an internet based self-help program for bipolar disorder. *J Affect Disord* 2015 Jan 15;171:13-21. [doi: [10.1016/j.jad.2014.08.008](https://doi.org/10.1016/j.jad.2014.08.008)] [Medline: [25282145](#)]
48. Tully L, de Leon E, Motoru S, Wahba K, Smith P, Singh K, et al. Using a novel mobile health application to monitor symptoms and functioning in an early psychosis program: Preliminary data on feasibility and acceptability. 2014 Presented at: 69th Society of Biological Psychiatry Annual Meeting 2014; May 8-12, 2014; New York City, New York URL: <https://f1000research.com/posters/1095564>
49. Stuart GW, Laraia MT, Ornstein SM, Nietert PJ. An interactive voice response system to enhance antidepressant medication compliance. *Top Health Inf Manage* 2003;24(1):15-20. [Medline: [12674391](#)]
50. Beebe L, Smith KD, Phillips C. A comparison of telephone and texting interventions for persons with schizophrenia spectrum disorders. *Issues Ment Health Nurs* 2014 May;35(5):323-329. [doi: [10.3109/01612840.2013.863412](https://doi.org/10.3109/01612840.2013.863412)] [Medline: [24766166](#)]
51. Skolarus LE, Piette JD, Pfeiffer PN, Williams LS, Mackey J, Hughes R, et al. Interactive voice response-an innovative approach to post-stroke depression self-management support. *Transl Stroke Res* 2017 Dec;8(1):77-82 [FREE Full text] [doi: [10.1007/s12975-016-0481-7](https://doi.org/10.1007/s12975-016-0481-7)] [Medline: [27394917](#)]
52. Krzystanek M, Krzeszowski D, Jagoda K, Krysta K. Long term telemedicine study of compliance in paranoid schizophrenia. *Psychiatr Danub* 2015 Sep;27 Suppl 1:S266-S268 [FREE Full text] [Medline: [26417777](#)]
53. Stentzel U, Grabe H, Strobel L, Penndorf P, Langosch J, Freyberger HJ, et al. Tecla: a telephone- and text-message based telemedical concept for patients with severe mental health disorders--study protocol for a controlled, randomized, study. *BMC Psychiatry* 2015 Nov 04;15:273 [FREE Full text] [doi: [10.1186/s12888-015-0659-7](https://doi.org/10.1186/s12888-015-0659-7)] [Medline: [26537570](#)]
54. Aschbrenner KA, Naslund JA, Gill LE, Bartels SJ, Ben-Zeev D. A qualitative study of client-clinician text exchanges in a mobile health intervention for individuals with psychotic disorders and substance use. *J Dual Diagn* 2016;12(1):63-71 [FREE Full text] [doi: [10.1080/15504263.2016.1145312](https://doi.org/10.1080/15504263.2016.1145312)] [Medline: [26829356](#)]
55. Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile assessment and treatment for schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. *Schizophr Bull* 2012 May;38(3):414-425 [FREE Full text] [doi: [10.1093/schbul/sbr155](https://doi.org/10.1093/schbul/sbr155)] [Medline: [22080492](#)]
56. Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. *Schizophr Res* 2007 Feb;90(1-3):229-237. [doi: [10.1016/j.schres.2006.11.015](https://doi.org/10.1016/j.schres.2006.11.015)] [Medline: [17208414](#)]
57. Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. *Schizophr Res* 2012 Feb;134(2-3):226-231. [doi: [10.1016/j.schres.2011.11.008](https://doi.org/10.1016/j.schres.2011.11.008)] [Medline: [22133906](#)]
58. Brain C, Sameby B, Allerby K, Lindström E, Eberhard J, Burns T, et al. Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia. *Eur Neuropsychopharmacol* 2014 Feb;24(2):215-222. [doi: [10.1016/j.euroneuro.2013.11.013](https://doi.org/10.1016/j.euroneuro.2013.11.013)] [Medline: [24359935](#)]
59. Schaefer MR, Wagoner ST, Young ME, Rawlinson AR, Kavookjian J, Shapiro SK, et al. Subjective versus objective measures of medication adherence in adolescents/young adults with attention-deficit hyperactivity disorder. *J Dev Behav Pediatr* 2019 Jan;40(1):54-59. [doi: [10.1097/DBP.0000000000000602](https://doi.org/10.1097/DBP.0000000000000602)] [Medline: [30001262](#)]
60. Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. *Psychiatr Serv* 2007 Jun;58(6):844-847. [doi: [10.1176/ps.2007.58.6.844](https://doi.org/10.1176/ps.2007.58.6.844)] [Medline: [17535946](#)]
61. Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. *Psychiatry Res* 2005 Feb 28;133(2-3):129-133. [doi: [10.1016/j.psychres.2004.11.002](https://doi.org/10.1016/j.psychres.2004.11.002)] [Medline: [15740989](#)]
62. Acosta FJ, Bosch E, Sarmiento G, Juanes N, Caballero-Hidalgo A, Mayans T. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. *Schizophr Res* 2009 Feb;107(2-3):213-217. [doi: [10.1016/j.schres.2008.09.007](https://doi.org/10.1016/j.schres.2008.09.007)] [Medline: [18849150](#)]
63. Kane JM, Perlis RH, DiCarlo LA, Au-Yeung K, Duong J, Petrides G. First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. *J Clin Psychiatry* 2013 Jun;74(6):e533-e540. [doi: [10.4088/JCP.12m08222](https://doi.org/10.4088/JCP.12m08222)] [Medline: [23842023](#)]
64. Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, et al. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. *JMIR Mhealth Uhealth* 2017 Feb 21;5(2):e18 [FREE Full text] [doi: [10.2196/mhealth.7030](https://doi.org/10.2196/mhealth.7030)] [Medline: [28223265](#)]
65. Schuman-Olivier Z, Borodovsky JT, Steinkamp J, Munir Q, Butler K, Greene MA, et al. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing

- buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study. *Addict Sci Clin Pract* 2018 Sep 24;13(1):21 [FREE Full text] [doi: [10.1186/s13722-018-0122-4](https://doi.org/10.1186/s13722-018-0122-4)] [Medline: [30249279](https://pubmed.ncbi.nlm.nih.gov/30249279/)]
66. DeWorsop D, Creatura G, Bluez G, Thurnauer H, Forselius-Bielen K, Ranganathan M, et al. Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. *Drug Alcohol Depend* 2016 Dec 1;163:24-30. [doi: [10.1016/j.drugalcdep.2016.02.045](https://doi.org/10.1016/j.drugalcdep.2016.02.045)] [Medline: [27068252](https://pubmed.ncbi.nlm.nih.gov/27068252/)]
  67. Galloway GP, Coyle JR, Guillén JE, Flower K, Mendelson JE. A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones. *J Addict Med* 2011 Sep;5(3):170-174 [FREE Full text] [doi: [10.1097/ADM.0b013e3181fcb5fd](https://doi.org/10.1097/ADM.0b013e3181fcb5fd)] [Medline: [21844832](https://pubmed.ncbi.nlm.nih.gov/21844832/)]
  68. Gordon JS, Armin JS, Cunningham JK, Muramoto ML, Christiansen SM, Jacobs TA. Lessons learned in the development and evaluation of RxCoach™, an mHealth app to increase tobacco cessation medication adherence. *Patient Educ Couns* 2017 Apr;100(4):720-727. [doi: [10.1016/j.pec.2016.11.003](https://doi.org/10.1016/j.pec.2016.11.003)] [Medline: [27839891](https://pubmed.ncbi.nlm.nih.gov/27839891/)]
  69. Oyama M, Hillhouse MP, Thomas C, Annon J, Hasson A, Mooney L, et al. Using cellphone technology to monitor and increase dosing adherence. *Drug Alcohol Depend* 2015 Nov;156:e168. [doi: [10.1016/j.drugalcdep.2015.07.457](https://doi.org/10.1016/j.drugalcdep.2015.07.457)]
  70. Sigmon SC, Meyer AC, Hruska B, Ochalek T, Heil SH, Higgins ST, et al. Interim buprenorphine treatment: leveraging technology to bridge waitlist delays. *Drug Alcohol Depend* 2015 Nov;156:e204. [doi: [10.1016/j.drugalcdep.2015.07.550](https://doi.org/10.1016/j.drugalcdep.2015.07.550)]
  71. Sigmon SC, Meyer AC, Hruska B, Ochalek T, Rose G, Badger GJ, et al. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility. *Addict Behav* 2015 Dec;51:136-142 [FREE Full text] [doi: [10.1016/j.addbeh.2015.07.030](https://doi.org/10.1016/j.addbeh.2015.07.030)] [Medline: [26256469](https://pubmed.ncbi.nlm.nih.gov/26256469/)]
  72. Kim E, Chocron SE, Ben-Yoav H, Winkler TE, Liu Y, Glassman M, et al. Programmable “Semismart” sensor: relevance to monitoring antipsychotics. *Adv Funct Mater* 2015 Feb 23;25(14):2156-2165. [doi: [10.1002/adfm.201403783](https://doi.org/10.1002/adfm.201403783)]
  73. Fletcher K, Stone E. New technology to support abstinence from alcohol, predict relapse and reduce outpatient costs. *Eur Psychiatry* 2015 Mar;30:1084. [doi: [10.1016/S0924-9338\(15\)30855-5](https://doi.org/10.1016/S0924-9338(15)30855-5)]
  74. Carlsson S, Olsson R, Lindkvist I, Beck O. Application of drug testing using exhaled breath for compliance monitoring of drug addicts in treatment. *Scand J Clin Lab Invest* 2015 Apr;75(2):156-161. [doi: [10.3109/00365513.2014.993336](https://doi.org/10.3109/00365513.2014.993336)] [Medline: [25562730](https://pubmed.ncbi.nlm.nih.gov/25562730/)]
  75. Patteet L, Maudens KE, Morrens M, Sabbe B, Dom G, Neels H. Determination of common antipsychotics in quantisal-collected oral fluid by UHPLC-MS/MS: method validation and applicability for therapeutic drug monitoring. *Ther Drug Monit* 2016 Feb;38(1):87-97. [doi: [10.1097/FTD.0000000000000242](https://doi.org/10.1097/FTD.0000000000000242)] [Medline: [26349083](https://pubmed.ncbi.nlm.nih.gov/26349083/)]
  76. Guinan TM, Neldner D, Stockham P, Kobus H, della Vedova CB, Voelcker NH. Porous silicon mass spectrometry as an alternative confirmatory assay for compliance testing of methadone. *Drug Test Anal* 2017 May;9(5):769-777. [doi: [10.1002/dta.2033](https://doi.org/10.1002/dta.2033)] [Medline: [27364015](https://pubmed.ncbi.nlm.nih.gov/27364015/)]
  77. Gottardo R, Fanigliulo A, Sorio D, Liotta E, Bortolotti F, Tagliaro F. Monitoring compliance to therapy during addiction treatments by means of hair analysis for drugs and drug metabolites using capillary zone electrophoresis coupled to time-of-flight mass spectrometry. *Forensic Sci Int* 2012 Mar 10;216(1-3):101-107. [doi: [10.1016/j.forsciint.2011.09.004](https://doi.org/10.1016/j.forsciint.2011.09.004)] [Medline: [21945303](https://pubmed.ncbi.nlm.nih.gov/21945303/)]
  78. Larabi IA, Abe E, Etting I, Alvarez J. Dosage de naltrexone dans les cheveux : intérêt comme marqueur de l’observance des patients au cours du traitement de l’alcool-dépendance (Naltrexone hair analysis as a tool to assess patient compliance in alcohol withdrawal treatment). *Toxicologie Analytique et Clinique* 2016 Dec;28(4):303-310. [doi: [10.1016/j.toxac.2016.06.001](https://doi.org/10.1016/j.toxac.2016.06.001)]
  79. Binz TM, Williner E, Strajhar P, Dolder PC, Liechti ME, Baumgartner MR, et al. Chiral analysis of amphetamines in hair by liquid chromatography-tandem mass spectrometry: compliance-monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse® therapy and identification after controlled low-dose application. *Drug Test Anal* 2018 Feb;10(2):254-261. [doi: [10.1002/dta.2208](https://doi.org/10.1002/dta.2208)] [Medline: [28440070](https://pubmed.ncbi.nlm.nih.gov/28440070/)]
  80. Leboulanger B, Aubry JM, Bondolfi G, Guy RH, Delgado-Charro MB. Lithium monitoring by reverse iontophoresis in vivo. *Clin Chem* 2004 Nov;50(11):2091-2100 [FREE Full text] [doi: [10.1373/clinchem.2004.034249](https://doi.org/10.1373/clinchem.2004.034249)] [Medline: [15192031](https://pubmed.ncbi.nlm.nih.gov/15192031/)]
  81. Kevin RC, Allsop DJ, Lintzeris N, Dunlop AJ, Booth J, McGregor IS. Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal. *Forensic Toxicol* 2016 Aug 4;35(1):33-44. [doi: [10.1007/s11419-016-0330-0](https://doi.org/10.1007/s11419-016-0330-0)]
  82. Sutherland JJ, Morrison RD, Daniels JS, Milne SB, Ryan TP. Managing psychotropic medications in complex, real-world patients using comprehensive therapeutic drug monitoring. *ACS Chem Neurosci* 2017 Dec 16;8(8):1641-1644. [doi: [10.1021/acchemneuro.7b00209](https://doi.org/10.1021/acchemneuro.7b00209)] [Medline: [28640591](https://pubmed.ncbi.nlm.nih.gov/28640591/)]
  83. Dunn KE, King VL, Brooner RK. Comparison of methods to assess psychiatric medication adherence in methadone-maintained patients with co-occurring psychiatric disorder. *Drug Alcohol Depend* 2016 Mar 1;160:212-217 [FREE Full text] [doi: [10.1016/j.drugalcdep.2016.01.016](https://doi.org/10.1016/j.drugalcdep.2016.01.016)] [Medline: [26851987](https://pubmed.ncbi.nlm.nih.gov/26851987/)]
  84. Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM. Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study. *Addict Behav* 2007 Apr;32(4):875-880. [doi: [10.1016/j.addbeh.2006.06.022](https://doi.org/10.1016/j.addbeh.2006.06.022)] [Medline: [16839698](https://pubmed.ncbi.nlm.nih.gov/16839698/)]

85. Schmitz JM, Sayre SL, Stotts AL, Rothfleisch J, Mooney ME. Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback. *J Behav Med* 2005 Apr;28(2):139-147. [doi: [10.1007/s10865-005-3663-4](https://doi.org/10.1007/s10865-005-3663-4)] [Medline: [15957569](https://pubmed.ncbi.nlm.nih.gov/15957569/)]
86. Schneider M, van Melle G, Uldry C, Huynh-Ba M, Fallab SC, Iorillo D, et al. Electronic monitoring of long-term use of the nicotine nasal spray and predictors of success in a smoking cessation program. *Nicotine Tob Res* 2003 Oct;5(5):719-727. [doi: [10.1080/14622200310001608545](https://doi.org/10.1080/14622200310001608545)] [Medline: [14577988](https://pubmed.ncbi.nlm.nih.gov/14577988/)]
87. Stoner SA, Arenella PB, Hendershot CS. Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders. *PLoS One* 2015;10(4):e0124613 [FREE Full text] [doi: [10.1371/journal.pone.0124613](https://doi.org/10.1371/journal.pone.0124613)] [Medline: [25909320](https://pubmed.ncbi.nlm.nih.gov/25909320/)]
88. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. *Value Health* 2003;6(5):566-573 [FREE Full text] [doi: [10.1046/j.1524-4733.2003.65269.x](https://doi.org/10.1046/j.1524-4733.2003.65269.x)] [Medline: [14627063](https://pubmed.ncbi.nlm.nih.gov/14627063/)]
89. Feinn R, Tennen H, Cramer J, Kranzler HR. Measurement and prediction of medication compliance in problem drinkers. *Alcohol Clin Exp Res* 2003 Aug;27(8):1286-1292. [doi: [10.1097/01.ALC.0000080670.59386.6E](https://doi.org/10.1097/01.ALC.0000080670.59386.6E)] [Medline: [12966323](https://pubmed.ncbi.nlm.nih.gov/12966323/)]
90. Tacke U, Uosukainen H, Kananen M, Kontra K, Pentikänen H. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination. *J Opioid Manag* 2009;5(6):321-329. [Medline: [20073406](https://pubmed.ncbi.nlm.nih.gov/20073406/)]
91. Mohr DC, Stiles-Shields C, Brenner C, Palac H, Montague E, Kaiser SM, et al. MedLink: a mobile intervention to address failure points in the treatment of depression in general medicine. In: Proceedings of the 9th International Conference on Pervasive Computing Technologies for Healthcare. 2015 May Presented at: PervasiveHealth'15; May 20-23, 2015; Istanbul, Turkey p. 100-107 URL: <http://europepmc.org/abstract/MED/26640740>
92. Sajatovic M, Levin JB, Sams J, Cassidy KA, Akagi K, Aebi ME, et al. Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. *Bipolar Disord* 2015 Sep;17(6):653-661 [FREE Full text] [doi: [10.1111/bdi.12326](https://doi.org/10.1111/bdi.12326)] [Medline: [26529124](https://pubmed.ncbi.nlm.nih.gov/26529124/)]
93. Sajatovic M, Davis MS, Cassidy KA, Nestor J, Sams J, Fuentes-Casiano E. A technology-enabled adherence enhancement system for people with bipolar disorder: results from a feasibility and patient acceptance analysis. *Patient Prefer Adherence* 2015;9:753-758 [FREE Full text] [doi: [10.2147/PPA.S81724](https://doi.org/10.2147/PPA.S81724)] [Medline: [26089652](https://pubmed.ncbi.nlm.nih.gov/26089652/)]
94. Acosta FJ, Ramallo-Fariña Y, Bosch E, Mayans T, Rodriguez CJ, Caravaca A. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®). *Schizophr Res* 2013 May;146(1-3):196-200 [FREE Full text] [doi: [10.1016/j.schres.2013.02.016](https://doi.org/10.1016/j.schres.2013.02.016)] [Medline: [23474024](https://pubmed.ncbi.nlm.nih.gov/23474024/)]
95. Stip E, Vincent PD, Sablier J, Guevremont C, Zhornitsky S, Tranulis C. A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia. *Front Pharmacol* 2013 Aug;4:100 [FREE Full text] [doi: [10.3389/fphar.2013.00100](https://doi.org/10.3389/fphar.2013.00100)] [Medline: [23950746](https://pubmed.ncbi.nlm.nih.gov/23950746/)]
96. Velligan D, Mintz J, Maples N, Xueying L, Gajewski S, Carr H, et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. *Schizophr Bull* 2013 Sep;39(5):999-1007 [FREE Full text] [doi: [10.1093/schbul/sbs116](https://doi.org/10.1093/schbul/sbs116)] [Medline: [23086987](https://pubmed.ncbi.nlm.nih.gov/23086987/)]
97. Fervaha G, Teo C, Mann S, Hahn M, Foussias G, Agid O, et al. Poster#195: examining levels of antipsychotic adherence to better understand nonadherence in patients with schizophrenia. *Schizophr Res* 2012 Apr;136(Suppl 1):S161 [FREE Full text] [doi: [10.1016/S0920-9964\(12\)70509-1](https://doi.org/10.1016/S0920-9964(12)70509-1)]
98. Guevremont C, Sablier J, Lum M, Vincent P, Tranulis C, Marcotte FN, et al. Dopill, an electronic pill dispenser, helping evaluate and control medication adherence in patients with schizophrenia. *Schizophr Res* 2010 Apr;117(2-3):278. [doi: [10.1016/j.schres.2010.02.450](https://doi.org/10.1016/j.schres.2010.02.450)]
99. Zhao Y, Moriwaki M, Kinoshita Y, Kawashima K, Ohga H, Tabuse H, et al. Maintaining favourable adherence by consistent self-administration of medication-medication event monitoring system (MEMS) trial to evaluate the compliance of patients with schizophrenia in Japan. *Schizophr Res* 2010 Apr;117(2-3):269 [FREE Full text] [doi: [10.1016/j.schres.2010.02.429](https://doi.org/10.1016/j.schres.2010.02.429)]
100. Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. *Schizophr Res* 2008 Mar;100(1-3):60-69 [FREE Full text] [doi: [10.1016/j.schres.2007.12.470](https://doi.org/10.1016/j.schres.2007.12.470)] [Medline: [18255269](https://pubmed.ncbi.nlm.nih.gov/18255269/)]
101. Nakonezny PA, Byerly MJ, Rush AJ. Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. *Psychiatry Res* 2008 Jan 15;157(1-3):259-263 [FREE Full text] [doi: [10.1016/j.psychres.2007.05.001](https://doi.org/10.1016/j.psychres.2007.05.001)] [Medline: [17935793](https://pubmed.ncbi.nlm.nih.gov/17935793/)]
102. Kozuki Y, Poupore E, Schepp K. Visual feedback therapy to enhance medication adherence in psychosis. *Arch Psychiatr Nurs* 2005 Apr;19(2):70-80. [doi: [10.1016/j.apnu.2005.02.008](https://doi.org/10.1016/j.apnu.2005.02.008)] [Medline: [15902676](https://pubmed.ncbi.nlm.nih.gov/15902676/)]
103. Kozuki Y, Schepp KG. Visual-feedback therapy for antipsychotic medication adherence. *Int Clin Psychopharmacol* 2006 Jan;21(1):57-61. [doi: [10.1097/01.yic.0000177016.59484.ce](https://doi.org/10.1097/01.yic.0000177016.59484.ce)] [Medline: [16317318](https://pubmed.ncbi.nlm.nih.gov/16317318/)]
104. Frangou S, Sachpazidis I, Stassinakis A, Sakas G. Telemonitoring of medication adherence in patients with schizophrenia. *Telemed J E Health* 2005 Dec;11(6):675-683. [doi: [10.1089/tmj.2005.11.675](https://doi.org/10.1089/tmj.2005.11.675)] [Medline: [16430387](https://pubmed.ncbi.nlm.nih.gov/16430387/)]
105. Ruskin PE, van der Wende J, Clark CR, Fenton J, Deveau J, Thapar R, et al. Feasibility of using the Med-eMonitor system in the treatment of schizophrenia: a pilot study. *Drug Inf J* 2016 Aug 28;37(3):283-291. [doi: [10.1177/009286150303700304](https://doi.org/10.1177/009286150303700304)]

106. Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, et al. Use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia. *J Psychiatry Neurosci* 2001 Sep;26(4):325-329 [[FREE Full text](#)] [Medline: [11590972](#)]
107. Peters-Strickland T, Pestreich L, Hatch A, Rohatagi S, Baker RA, Docherty JP, et al. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. *Neuropsychiatr Dis Treat* 2016;12:2587-2594 [[FREE Full text](#)] [doi: [10.2147/NDT.S116029](#)] [Medline: [27785036](#)]
108. Kopelowicz A, Baker RA, Zhao C, Brewer C, Lawson E, Peters-Strickland T. A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness. *Neuropsychiatr Dis Treat* 2017;13:2641-2651 [[FREE Full text](#)] [doi: [10.2147/NDT.S143091](#)] [Medline: [29089771](#)]
109. Profit D, Rohatagi S, Zhao C, Hatch A, Docherty JP, Peters-Strickland TS. Developing a digital medicine system in psychiatry: ingestion detection rate and latency period. *J Clin Psychiatry* 2016 Dec;77(9):e1095-e1100 [[FREE Full text](#)] [doi: [10.4088/JCP.16m10643](#)] [Medline: [27379966](#)]
110. Thompson N, Nazir N, Cox LS, Faseru B, Goggin K, Ahluwalia JS, et al. Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. *Patient Prefer Adherence* 2011;5:475-482 [[FREE Full text](#)] [doi: [10.2147/PPA.S24023](#)] [Medline: [22003285](#)]
111. Patel UB, Ni Q, Clayton C, Lam P, Parks J. An attempt to improve antipsychotic medication adherence by feedback of medication possession ratio scores to prescribers. *Popul Health Manag* 2010 Oct;13(5):269-274. [doi: [10.1089/pop.2009.0053](#)] [Medline: [20879908](#)]
112. Rosen CS, Azevedo KJ, Tiet QQ, Greene CJ, Wood AE, Calhoun P, et al. An RCT of effects of telephone care management on treatment adherence and clinical outcomes among veterans with PTSD. *Psychiatr Serv* 2017 Dec 1;68(2):151-158. [doi: [10.1176/appi.ps.201600069](#)] [Medline: [27745535](#)]
113. Guarino H, Acosta M, Marsch LA, Xie H, Aponte-Melendez Y. A mixed-methods evaluation of the feasibility, acceptability, and preliminary efficacy of a mobile intervention for methadone maintenance clients. *Psychol Addict Behav* 2016 Feb;30(1):1-11 [[FREE Full text](#)] [doi: [10.1037/adb0000128](#)] [Medline: [26618796](#)]
114. McClure JB, Anderson ML, Bradley K, An LC, Catz SL. Evaluating an adaptive and interactive mHealth smoking cessation and medication adherence program: a randomized pilot feasibility study. *JMIR Mhealth Uhealth* 2016 Aug 3;4(3):e94 [[FREE Full text](#)] [doi: [10.2196/mhealth.6002](#)] [Medline: [27489247](#)]
115. Beebe LH, Smith K, Crye C, Addonizio C, Strunk DJ, Martin W, et al. Telenursing intervention increases psychiatric medication adherence in schizophrenia outpatients. *J Am Psychiatr Nurses Assoc* 2008 Jun;14(3):217-224. [doi: [10.1177/1078390308318750](#)] [Medline: [21665767](#)]
116. Niendam TA, Tully LM, Iosif A, Kumar D, Nye KE, Denton JC, et al. Enhancing early psychosis treatment using smartphone technology: a longitudinal feasibility and validity study. *J Psychiatr Res* 2018 Jan;96:239-246. [doi: [10.1016/j.jpsychires.2017.10.017](#)] [Medline: [29126059](#)]
117. Manuel JM, Maurino J, Diez T, Saiz-Ruiz J. Factors associated with the effectiveness of a telephone-based nursing strategy for enhancing medication adherence in schizophrenia. *Clin Pract Epidemiol Ment Health* 2011;7:117-119 [[FREE Full text](#)] [doi: [10.2174/1745017901107010117](#)] [Medline: [21760832](#)]
118. Kreyenbuhl J, Record EJ, Himelhoch S, Charlotte M, Palmer-Bacon J, Dixon LB, et al. Development and feasibility testing of a smartphone intervention to improve adherence to antipsychotic medications. *Clin Schizophr Relat Psychoses* 2016 Jul 25. [doi: [10.3371/CSRP.KRRE.070816](#)] [Medline: [27454213](#)]
119. Gervasoni N, Legendre-Simon P, Aubry J, Gex-Fabry M, Bertschy G, Bondolfi G. Early telephone intervention for psychiatric outpatients starting antidepressant treatment. *Nord J Psychiatry* 2010 Aug;64(4):265-267. [doi: [10.3109/08039480903528641](#)] [Medline: [20166864](#)]
120. Faurholt-Jepsen M, Frost M, Ritz C, Christensen EM, Jacoby AS, Mikkelsen RL, et al. Daily electronic self-monitoring in bipolar disorder using smartphones-the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial. *Psychol Med* 2015 Oct;45(13):2691-2704. [doi: [10.1017/S0033291715000410](#)] [Medline: [26220802](#)]
121. Chang TE, Jing Y, Yeung AS, Brenneman SK, Kalsekar ID, Hebden T, et al. Depression monitoring and patient behavior in the Clinical Outcomes in Measurement-Based Treatment (COMET) trial. *Psychiatr Serv* 2014 Aug 1;65(8):1058-1061. [doi: [10.1176/appi.ps.201300326](#)] [Medline: [25082605](#)]
122. Bhat S, Chow Z, Heath L, Billups S, Trinkley K, Loeb D. Springer Link. 2017. A collaborative telehealth antidepressant monitoring program involving pharmacists in primary care URL: <https://link.springer.com/content/pdf/10.1007%2Fs11606-017-4028-8.pdf> [[WebCite Cache ID 72hfX13Rj](#)]
123. Gustafson DH, Landucci G, McTavish F, Kornfield R, Johnson RA, Mares M, et al. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. *Trials* 2016 Dec 12;17(1):592 [[FREE Full text](#)] [doi: [10.1186/s13063-016-1726-1](#)] [Medline: [27955689](#)]
124. Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. *Psychiatry Res* 2012 Dec 30;200(2-3):89-95. [doi: [10.1016/j.psychres.2012.07.034](#)] [Medline: [22901437](#)]

125. Xu DR, Gong W, Caine ED, Xiao S, Hughes JP, Ng M, et al. Lay health supporters aided by a mobile phone messaging system to improve care of villagers with schizophrenia in Liuyang, China: protocol for a randomised control trial. *BMJ Open* 2016 Jan 20;6(1):e010120 [FREE Full text] [doi: [10.1136/bmjopen-2015-010120](https://doi.org/10.1136/bmjopen-2015-010120)] [Medline: [26792221](https://pubmed.ncbi.nlm.nih.gov/26792221/)]
126. Applegate B, Raymond C, Collado-Rodriguez A, Riley W, Schneider N. Improving adherence to nicotine gum by SMS text messaging: a pilot study (RPOS3-57). 2007 Presented at: Society for Research on Nicotine and Tobacco 13th Annual Meeting; February 20-24, 2007; Austin, Texas p. 21-24 URL: [https://cdn.ymaws.com/srnt.site-ym.com/resource/resmgr/Conferences/Past\\_Annual\\_Meetings/2007\\_Annual\\_Meeting\\_Abstract.pdf](https://cdn.ymaws.com/srnt.site-ym.com/resource/resmgr/Conferences/Past_Annual_Meetings/2007_Annual_Meeting_Abstract.pdf)
127. Tseng T, Krebs P, Schoenthaler A, Wong S, Sherman S, Gonzalez M, et al. Combining text messaging and telephone counseling to increase varenicline adherence and smoking abstinence among cigarette smokers living with HIV: a randomized controlled study. *AIDS Behav* 2017 Jul;21(7):1964-1974 [FREE Full text] [doi: [10.1007/s10461-016-1538-z](https://doi.org/10.1007/s10461-016-1538-z)] [Medline: [27605365](https://pubmed.ncbi.nlm.nih.gov/27605365/)]
128. Kannisto KA, Adams CE, Koivunen M, Katajisto J, Välimäki M. Feedback on SMS reminders to encourage adherence among patients taking antipsychotic medication: a cross-sectional survey nested within a randomised trial. *BMJ Open* 2015;5(11):e008574 [FREE Full text] [doi: [10.1136/bmjopen-2015-008574](https://doi.org/10.1136/bmjopen-2015-008574)] [Medline: [26553830](https://pubmed.ncbi.nlm.nih.gov/26553830/)]
129. Välimäki M, Kannisto KA, Vahlberg T, Hätönen H, Adams CE. Short text messages to encourage adherence to medication and follow-up for people with psychosis (Mobile.Net): randomized controlled trial in. *J Med Internet Res* 2017 Jul 12;19(7):e245 [FREE Full text] [doi: [10.2196/jmir.7028](https://doi.org/10.2196/jmir.7028)] [Medline: [28701292](https://pubmed.ncbi.nlm.nih.gov/28701292/)]
130. Nye I. Local NGO/government partnership addresses medication non-adherence in psychiatric outpatients: Results from a reminder and support pilot intervention. 2014 Jul 29 Presented at: National Congress of South African Society of Psychiatrists (SASOP); September 3-7, 2014; Durban, South Africa p. 112. [doi: [10.7196/SAJP.664](https://doi.org/10.7196/SAJP.664)]
131. van Gent E, van der Klein E. Taylor & Francis Online. Improving compliance and treatment outcome in bipolar and schizophrenic patients by using short message text service (SMS) URL: <https://www.tandfonline.com/doi/abs/10.3109/13651501.2010.527734?scroll=top&needAccess=true&journalCode=ijpc20> [accessed 2018-09-25] [WebCite Cache ID [72heodgJX](https://www.webcitation.org/72heodgJX)]
132. Pijnenborg GH, Withaar FK, Brouwer WH, Timmerman ME, van den Bosch RJ, Evans JJ. The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. *Br J Clin Psychol* 2010 Jun;49(Pt 2):259-274. [doi: [10.1348/014466509X467828](https://doi.org/10.1348/014466509X467828)] [Medline: [19735607](https://pubmed.ncbi.nlm.nih.gov/19735607/)]
133. Vora A, Smalligan R, Chandra R, James S, Frost J, Basinger R, et al. A smoking cessation model that integrates social media in hospitalized patients post-discharge. In: *Pharmacotherapy*. 2014 Presented at: Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP); October 12-15, 2014; Austin, Texas.
134. Brendryen H, Kraft P. Happy ending: a randomized controlled trial of a digital multi-media smoking cessation intervention. *Addiction* 2008 Mar;103(3):478-484. [doi: [10.1111/j.1360-0443.2007.02119.x](https://doi.org/10.1111/j.1360-0443.2007.02119.x)] [Medline: [18269367](https://pubmed.ncbi.nlm.nih.gov/18269367/)]
135. Yuhongxia L. The compliance of varenicline usage and the smoking abstinence rate via mobile phone text messaging combine with varenicline: A single-blind, randomised control trial. 2011 Presented at: 16th Congress of the Asian Pacific Society of Respiriology; November 3-6, 2011; Shanghai, China. [doi: [10.1111/j.1440-1843.2011.02071.x](https://doi.org/10.1111/j.1440-1843.2011.02071.x)]
136. Wenze SJ, Army MF, Miller IW. Feasibility and acceptability of a mobile intervention to improve treatment adherence in bipolar disorder: a pilot study. *Behav Modif* 2014 Jan 8;38(4):497-515. [doi: [10.1177/0145445513518421](https://doi.org/10.1177/0145445513518421)] [Medline: [24402464](https://pubmed.ncbi.nlm.nih.gov/24402464/)]
137. Wenze SJ, Army MF, Weinstock LM, Gaudiano BA, Miller IW. An open trial of a smartphone-assisted, adjunctive intervention to improve treatment adherence in bipolar disorder. *J Psychiatr Pract* 2016 Dec;22(6):492-504 [FREE Full text] [doi: [10.1097/PRA.000000000000196](https://doi.org/10.1097/PRA.000000000000196)] [Medline: [27824786](https://pubmed.ncbi.nlm.nih.gov/27824786/)]
138. Aikens JE, Trivedi R, Heapy A, Pfeiffer PN, Piette JD. Potential impact of incorporating a patient-selected support person into mHealth for depression. *J Gen Intern Med* 2015 Jun;30(6):797-803. [doi: [10.1007/s11606-015-3208-7](https://doi.org/10.1007/s11606-015-3208-7)] [Medline: [25666218](https://pubmed.ncbi.nlm.nih.gov/25666218/)]
139. Ben-Zeev D, Kaiser SM, Krzos I. Remote "hovering" with individuals with psychotic disorders and substance use: feasibility, engagement, and therapeutic alliance with a text-messaging mobile interventionist. *J Dual Diagn* 2014;10(4):197-203 [FREE Full text] [doi: [10.1080/15504263.2014.962336](https://doi.org/10.1080/15504263.2014.962336)] [Medline: [25391277](https://pubmed.ncbi.nlm.nih.gov/25391277/)]
140. Bickmore TW, Puskar K, Schlenk EA, Pfeifer LM, Sereika SM. Maintaining reality: Relational agents for antipsychotic medication adherence. *Interact Comput* 2010 Jul;22(4):276-288. [doi: [10.1016/j.intcom.2010.02.001](https://doi.org/10.1016/j.intcom.2010.02.001)]
141. Puskar K, Schlenk EA, Callan J, Bickmore T, Sereika S. Relational agents as an adjunct in schizophrenia treatment. *J Psychosoc Nurs Ment Health Serv* 2011 Aug;49(8):22-29. [doi: [10.3928/02793695-20110705-01](https://doi.org/10.3928/02793695-20110705-01)] [Medline: [21766736](https://pubmed.ncbi.nlm.nih.gov/21766736/)]
142. Graham AL, Papandonatos GD, Cha S, Erar B, Amato MS, Cobb NK, et al. Improving adherence to smoking cessation treatment: intervention effects in a web-based randomized trial. *Nicotine Tob Res* 2017 Mar 1;19(3):324-332. [doi: [10.1093/ntr/ntw282](https://doi.org/10.1093/ntr/ntw282)] [Medline: [27836982](https://pubmed.ncbi.nlm.nih.gov/27836982/)]
143. D'Souza R. Improving treatment adherence and longitudinal outcomes in patients with a serious mental illness by using telemedicine. *J Telemed Telecare* 2002;8 Suppl 2:113-115. [doi: [10.1177/1357633X020080S251](https://doi.org/10.1177/1357633X020080S251)] [Medline: [12217162](https://pubmed.ncbi.nlm.nih.gov/12217162/)]
144. Piette JD, Aikens JE, Trivedi R, Parrish D, Standiford C, Marinec NS, et al. Depression self-management assistance using automated telephonic assessments and social support. *Am J Manag Care* 2013 Nov;19(11):892-900 [FREE Full text] [Medline: [24511987](https://pubmed.ncbi.nlm.nih.gov/24511987/)]

145. Pfeiffer PN, Valenstein M, Ganoczy D, Henry J, Dobscha SK, Piette JD. Pilot study of enhanced social support with automated telephone monitoring after psychiatric hospitalization for depression. *Soc Psychiatry Psychiatr Epidemiol* 2017 Dec;52(2):183-191. [doi: [10.1007/s00127-016-1288-2](https://doi.org/10.1007/s00127-016-1288-2)] [Medline: [27783130](https://pubmed.ncbi.nlm.nih.gov/27783130/)]
146. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. *Am J Prev Med* 2010 May;38(5):482-490 [FREE Full text] [doi: [10.1016/j.amepre.2010.01.024](https://doi.org/10.1016/j.amepre.2010.01.024)] [Medline: [20409497](https://pubmed.ncbi.nlm.nih.gov/20409497/)]
147. Meglic M, Furlan M, Kuzmanic M, Kozel D, Baraga D, Kuhar I, et al. Feasibility of an eHealth service to support collaborative depression care: results of a pilot study. *J Med Internet Res* 2010;12(5):e63 [FREE Full text] [doi: [10.2196/jmir.1510](https://doi.org/10.2196/jmir.1510)] [Medline: [21172765](https://pubmed.ncbi.nlm.nih.gov/21172765/)]
148. Castle T, Cunningham MA, Marsh GM. Antidepressant medication adherence via interactive voice response telephone calls. *Am J Manag Care* 2012 Sep 1;18(9):e346-e355 [FREE Full text] [Medline: [23009333](https://pubmed.ncbi.nlm.nih.gov/23009333/)]
149. Cook PF, Emiliozzi S, Waters C, el Hajj D. Effects of telephone counseling on antipsychotic adherence and emergency department utilization. *Am J Manag Care* 2008 Dec;14(12):841-846 [FREE Full text] [Medline: [19067501](https://pubmed.ncbi.nlm.nih.gov/19067501/)]
150. Yakirevitch J, Marchevsky S, Abramovitch Y, Kotler M. P03-153-Special informative internet site for schizophrenic patients: its feasibility and contribution to pharmacotherapy. *Eur Psychiatry* 2010;25(Suppl 1):1134 [FREE Full text] [doi: [10.1016/S0924-9338\(10\)71123-8](https://doi.org/10.1016/S0924-9338(10)71123-8)]
151. Atherton-Naji A, Hamilton R, Riddle W, Naji S. Improving adherence to antidepressant drug treatment in primary care: a feasibility study for a randomized controlled trial of educational intervention. *Prim Care Psych* 2001;7(2):61-67 [FREE Full text] [doi: [10.1185/135525701750384473](https://doi.org/10.1185/135525701750384473)]
152. Rickles NM, Svarstad BL, Statz-Paynter JL, Taylor LV, Kobak KA. Pharmacist telemonitoring of antidepressant use: effects on pharmacist-patient collaboration. *J Am Pharm Assoc (2003)* 2005;45(3):344-353. [Medline: [15991756](https://pubmed.ncbi.nlm.nih.gov/15991756/)]
153. Perahia DG, Quail D, Gandhi P, Walker DJ, Peveler RC. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. *J Affect Disord* 2008 May;108(1-2):33-41 [FREE Full text] [doi: [10.1016/j.jad.2007.08.023](https://doi.org/10.1016/j.jad.2007.08.023)] [Medline: [17905442](https://pubmed.ncbi.nlm.nih.gov/17905442/)]
154. Fortney JC, Pyne JM, Kimbrell TA, Hudson TJ, Robinson DE, Schneider R, et al. Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial. *JAMA Psychiatry* 2015 Jan;72(1):58-67. [doi: [10.1001/jamapsychiatry.2014.1575](https://doi.org/10.1001/jamapsychiatry.2014.1575)] [Medline: [25409287](https://pubmed.ncbi.nlm.nih.gov/25409287/)]
155. Ruetsch C, Tkacz J, McPherson TL, Cacciola J. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up. *Addict Behav* 2012 May;37(5):686-689. [doi: [10.1016/j.addbeh.2012.01.013](https://doi.org/10.1016/j.addbeh.2012.01.013)] [Medline: [22348921](https://pubmed.ncbi.nlm.nih.gov/22348921/)]
156. Gong J, Baker CL, Zou KH, Bruno M, Jumadilova Z, Lawrence D, et al. A pragmatic randomized trial comparing telephone-based enhanced pharmacy care and usual care to support smoking cessation. *J Manag Care Spec Pharm* 2016 Dec;22(12):1417-1425 [FREE Full text] [doi: [10.18553/jmcp.2016.22.12.1417](https://doi.org/10.18553/jmcp.2016.22.12.1417)] [Medline: [27882838](https://pubmed.ncbi.nlm.nih.gov/27882838/)]
157. Fortney JC, Pyne JM, Edlund MJ, Williams DK, Robinson DE, Mittal D, et al. A randomized trial of telemedicine-based collaborative care for depression. *J Gen Intern Med* 2007 Aug;22(8):1086-1093 [FREE Full text] [doi: [10.1007/s11606-007-0201-9](https://doi.org/10.1007/s11606-007-0201-9)] [Medline: [17492326](https://pubmed.ncbi.nlm.nih.gov/17492326/)]
158. Ruskin PE, Silver-Aylaian M, Kling MA, Reed SA, Bradham DD, Hebel JR, et al. Treatment outcomes in depression: comparison of remote treatment through telepsychiatry to in-person treatment. *Am J Psychiatry* 2004 Aug;161(8):1471-1476. [doi: [10.1176/appi.ajp.161.8.1471](https://doi.org/10.1176/appi.ajp.161.8.1471)] [Medline: [15285975](https://pubmed.ncbi.nlm.nih.gov/15285975/)]
159. Hungerbuehler I, Valiengo L, Loch AA, Rössler W, Gattaz WF. Home-based psychiatric outpatient care through videoconferencing for depression: a randomized controlled follow-up trial. *JMIR Ment Health* 2016 Aug 3;3(3):e36 [FREE Full text] [doi: [10.2196/mental.5675](https://doi.org/10.2196/mental.5675)] [Medline: [27489204](https://pubmed.ncbi.nlm.nih.gov/27489204/)]
160. Grady BJ, Melcer T. A retrospective evaluation of telemental healthcare services for remote military populations. *Telemed J E Health* 2005 Oct;11(5):551-558. [doi: [10.1089/tmj.2005.11.551](https://doi.org/10.1089/tmj.2005.11.551)] [Medline: [16250818](https://pubmed.ncbi.nlm.nih.gov/16250818/)]
161. Farabee D, Calhoun S, Veliz R. An experimental comparison of telepsychiatry and conventional psychiatry for parolees. *Psychiatr Serv* 2016 Dec 1;67(5):562-565. [doi: [10.1176/appi.ps.201500025](https://doi.org/10.1176/appi.ps.201500025)] [Medline: [26725291](https://pubmed.ncbi.nlm.nih.gov/26725291/)]
162. Beebe LH, Smith K, Phillips C. Effect of a telephone intervention on measures of psychiatric and nonpsychiatric medication adherence in outpatients with schizophrenia spectrum disorders. *J Psychosoc Nurs Ment Health Serv* 2017 Jan 1;55(1):29-36. [doi: [10.3928/02793695-20170119-04](https://doi.org/10.3928/02793695-20170119-04)] [Medline: [28135389](https://pubmed.ncbi.nlm.nih.gov/28135389/)]
163. Scheurer D, Choudhry N, Swanton KA, Matlin O, Shrank W. Association between different types of social support and medication adherence. *Am J Manag Care* 2012 Dec 1;18(12):e461-e467 [FREE Full text] [Medline: [23286676](https://pubmed.ncbi.nlm.nih.gov/23286676/)]
164. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. *Ann Pharmacother* 1998;32(7-8):749-754. [doi: [10.1345/aph.17423](https://doi.org/10.1345/aph.17423)] [Medline: [9681089](https://pubmed.ncbi.nlm.nih.gov/9681089/)]
165. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. *Chest* 2011 Aug;140(2):425-432. [doi: [10.1378/chest.09-3074](https://doi.org/10.1378/chest.09-3074)] [Medline: [21330381](https://pubmed.ncbi.nlm.nih.gov/21330381/)]

## Abbreviations

**AI:** artificial intelligence  
**ADHD:** attention deficit hyperactivity disorder  
**CBT:** cognitive behavioral therapy  
**CENTRAL:** Cochrane Central Register of Controlled Trials  
**CV:** computer vision  
**IVR:** interactive voice response  
**MEMS:** Medication Event Monitoring System  
**PTSD:** posttraumatic stress disorder  
**RCTs:** randomized controlled trials  
**SMS:** short messaging service

*Edited by J Torous; submitted 17.10.18; peer-reviewed by S Acquilano, P Batterham; comments to author 28.11.18; accepted 13.12.18; published 12.03.19*

*Please cite as:*

*Steinkamp JM, Goldblatt N, Borodovsky JT, LaVertu A, Kronish IM, Marsch LA, Schuman-Olivier Z  
Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review  
JMIR Ment Health 2019;6(3):e12493  
URL: <http://mental.jmir.org/2019/3/e12493/>  
doi: [10.2196/12493](https://doi.org/10.2196/12493)  
PMID:*

©Jackson M Steinkamp, Nathaniel Goldblatt, Jacob T Borodovsky, Amy LaVertu, Ian M Kronish, Lisa A Marsch, Zev Schuman-Olivier. Originally published in JMIR Mental Health (<http://mental.jmir.org>), 12.03.2019. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Mental Health, is properly cited. The complete bibliographic information, a link to the original publication on <http://mental.jmir.org/>, as well as this copyright and license information must be included.